5BARz International 10-K 14 Apr 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Mar. 15, 2014	Jun. 30, 2013
Document And Entity Information	'	'	'
Entity Registrant Name	'5Barz International, Inc.	'	'
Entity Central Index Key	'0001454124	'	'
Document Type	'10-K	'	'
Document Period End Date	31-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-31	'	'
Is Entity a Well-known Seasoned Issuer?	'No	'	'
Is Entity a Voluntary Filer?	'No	'	'
Is Entity's Reporting Status Current?	'No	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$15,481,059
Entity Common Stock, Shares Outstanding	'	175,773,105	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
CURRENT ASSETS:	'	'
Cash	$450,215	$48,308
Inventories	161,900	'
Note receivable	65,000	'
Prepaid expenses and deposits	62,981	22,156
TOTAL CURRENT ASSETS	740,096	70,464
FIXED ASSETS:	'	'
Furniture & equipment, net	225,983	4,406
OTHER ASSETS:	'	'
Intangible assets	3,387,406	3,387,406
Goodwill	1,140,246	1,140,246
TOTAL OTHER ASSETS	4,527,652	4,527,652
TOTAL ASSETS	5,493,731	4,602,522
CURRENT LIABILITIES:	'	'
Accounts payable and accrued expenses	1,450,167	2,445,410
Due to escrow agent	52,321	52,321
Derivative liabilities	60,018	'
Lease obligation ( current portion )	60,000	'
Notes payable	410,183	993,554
TOTAL CURRENT LIABILITIES	2,032,689	3,491,285
Related party loans	'	19,850
Lease obligation (non- current portion )	100,464	'
TOTAL LIABILITIES	2,133,153	3,511,135
STOCKHOLDERS' EQUITY	'	'
Common stock, $.001 par value, 250,000,000 shares authorized; 163,909,191 and 117,418,281 shares issued and outstanding as of December 31, 2013 and December 31, 2012, respectively	163,909	117,418
Capital in excess of par value	7,721,140	3,226,802
Deficit accumulated during the development stage	-5,173,598	-2,971,099
Accumulated other comprehensive income	29,234	4,272
Non-controlling interest	619,893	713,994
TOTAL STOCKHOLDERS' EQUITY	3,360,578	1,091,387
TOTAL AND STOCKHOLDERS' EQUITY	$5,493,731	$4,602,522

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]	'	'
Common stock, par value	$0.00	$0.00
Common stock, authorized	250,000,000	250,000,000
Common stock, issued	163,909,191	117,418,281
Common stock,outstanding	163,909,191	117,418,281

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	12 Months Ended		62 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Income Statement [Abstract]	'	'	'
Sales	'	'	'
Cost of Sales	'	'	'
Gross profit	'	'	'
Operating expenses:	'	'	'
Amortization and depreciation	10,512	3,520	15,085
Bank charges and interest	59,056	192,466	294,919
Sales and marketing expenses	194,750	114,672	539,163
Research & development	641,892	0	641,892
General and administrative expenses	1,792,946	2,053,678	4,427,343
Stock based compensation	601,113	'	601,113
Total operating expenses	3,300,269	2,364,336	6,519,515
(Loss) from operations	-3,300,269	-2,364,336	-6,519,515
Other income (expense):	'	'	'
Interest income	'	'	16,666
Currency gains (losses)	'	-5,215	-567
Change in fair value of derivative liability	-60,018	630,086	570,068
Amortization of debt discount on derivative liability	'	-132,897	-132,897
Loss on termination of finance agreements	'	-152,676	-152,676
Loss on conversion of debt	'	'	-17,500
Change in warrant liability	8,178	-2,355	5,823
Gain on debt settlements	1,073,009	'	1,072,227
Total Other income	-1,003,669	-336,943	-1,361,145
Net (loss) before non-controlling interest	-2,296,600	-2,027,393	-5,158,370
Non-controlling interest share of net loss	-94,101	109,329	15,228
Net loss after non-controlling interest	-2,202,499	-2,136,722	-5,173,598
Basic loss per common share	($0.02)	($0.02)	'
Weighted average number of shares outstanding	126,639,034	97,532,158	'
Other comprehensive income	'	'	'
Foreign currency translation gain	24,962	4,272	'
Other comprehensive income	24,962	4,272	'
Comprehensive loss	($2,177,537)	($2,132,450)	'

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	12 Months Ended		62 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'	'
Net loss	($2,296,600)	($2,027,393)	($5,158,370)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Amortization & depreciation	10,512	3,520	14,501
Amortization of debt discount	'	132,897	132,897
Non - controlling interest share of net loss	'	'	-257
Stock based compensation	601,113	7,113	608,226
Change in fair value of derivative liability	60,018	-541,450	-481,432
Change in debt discount on convertible notes	'	20,180	20,180
Change in warrant liability	-8,178	14,968	6,790
Common shares issued for services	228,740	798,463	1,034,703
Gain on settlement of debts	-1,073,009	'	-1,073,009
Changes in operating assets and liabilities:	'	'	'
Change in inventory	-161,900	'	-161,900
Change in note receivable	-65,000	'	-65,000
Change in accounts payable and accrued expenses	406,397	379,118	1,021,961
Change in prepaid expenses and deposits	-40,825	-2,997	-43,822
Change in unpaid interest and penalties on notes payable	108,377	359,698	490,908
Change in amount due to escrow agent	'	-712	52,321
Net cash from (used in) operating activities	-2,230,355	-856,594	-3,601,301
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'	'
Deposit on investment in CelLynx	'	'	-170,000
Cash in CelLynx - date of acquisition	'	3,260	3,260
Acquisition of intangible assets	'	-4,808	-4,808
Purchase of furniture and equipment assets	-62,293	'	-66,946
Net cash used in investing activities	-62,293	-1,548	-238,494
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'	'
Payments under line of credit agreement CelLynx	'	'	-250,152
Payment of amount due to CelLynx - intellectual property acquisition	'	'	-242,865
Proceeds from issuance of convertible notes	35,000	293,500	442,139
Payments of amounts due to related party	-19,850	-100,587	-464,172
Proceeds used to settle notes payable	-357,583	-68,318	-425,901
Proceeds from issuance of common stock	2,930,750	520,000	4,840,597
Proceeds from issuance of common stock by subsidiary - 5BARz AG	91,276	203,230	371,131
Principal payments of capital leases	-10,000	'	-10,000
Subscription receivable	'	5,144	'
Net cash provided by financing activities	2,669,593	852,969	4,270,777
Effect of foreign currency exchange	24,962	4,272	29,234
NET INCREASE IN CASH	401,907	-901	450,215
CASH, BEGINNING OF PERIOD	48,308	49,209	0
CASH, END OF PERIOD	450,215	48,308	450,215
Supplementary disclosure of Cash Flow Information	'	'	'
Cash paid for interest	8,915	17,506	69,818
NON-CASH INVESTING AND FINANCING ACTIVITIES	'	'	'
Common stock issued upon acquisition of CelLynx Group, Inc.	'	250,000	250,000
Settlement of prepaid deposit upon acquisition of CelLynx Group, Inc.	'	170,000	170,000
Fair market value of notes converted upon acquisition of CelLynx Group, Inc.	'	455,000	455,000
Fair market value of net assets acquired	'	875,000	875,000
Conversion of notes payable - CelLynx Group,Inc. & 5BARz	30,500	69,900	100,400
Investment in CelLynx intellectual property for shares	'	1,800,000	1,800,000
Replacement of common shares acquired with a convertible note	80,000	'	80,000
Issuance of convertible note in lieu of accounts payable	147,428	'	147,428
Shares issued to settle interest on notes payable	7,500	'	7,500
Settlement of accounts payable with common stock	1,270,193	'	1,270,193
Settlement of notes payable with common stock	514,398	'	514,398
Lease obligation	$160,464	'	$160,464

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders Equity (USD $)	Common Stock	Excess of Par Value	Subscription Receivable	Deficit Accumulated During Development Stage	Noncontrolling Interest	Other Comprehensive Income	Total
Beginning Balance, Amount at Nov. 16, 2008	'	'	'	'	'	'	'
Founder Shares Issued, Shares	7,100,000	'	'	'	'	'	'
Founder Shares Issued, Amount	$7,100	'	'	'	'	'	$7,100
Issuance of Common Stock , shares	1,776,100	'	'	'	'	'	'
Issuance of Common Stock , amount	1,776	15,969	'	'	'	'	17,745
Stock Subscription Receivable	'	'	-425	'	'	'	-425
Net loss	'	'	'	-4,888	'	'	-4,888
Ending Balance, Amount at Dec. 31, 2008	8,876	15,969	-425	-4,888	'	'	19,532
Ending Balance, Shares at Dec. 31, 2008	8,876,100	'	'	'	'	'	'
Stock Subscription Receivable	'	'	425	'	'	'	425
Net loss	'	'	'	-19,220	'	'	-19,220
Ending Balance, Amount at Dec. 31, 2009	8,876	15,969	'	-24,108	'	'	737
Beginning Balance, Shares at Dec. 31, 2009	8,876,100	'	'	'	'	'	'
Initiated 18:1 stock split, Shares	150,893,700	'	'	'	'	'	'
Initiated 18:1 stock split, Amount	150,894	-150,894	'	'	'	'	'
Shares cancelled, Shares	-87,800,000	'	'	'	'	'	'
Shares cancelled, Amount	-87,800	87,800	'	'	'	'	'
Issuance of Common Stock , shares	15,600,000	'	'	'	'	'	'
Issuance of Common Stock , amount	15,600	-1,950	'	'	'	'	13,650
Net loss	'	'	'	-29,122	'	'	-29,122
Ending Balance, Amount at Dec. 31, 2010	87,570	-49,075	'	-53,230	'	'	-14,735
Ending Balance, Shares at Dec. 31, 2010	87,500,000	'	'	'	'	'	'
Beginning Balance, Amount at Nov. 30, 2010	'	'	'	'	'	'	'
Shares issued - Investement in CelLynx Group Inc, shares	15,600,000	'	'	'	'	'	'
Ending Balance, Amount at Dec. 31, 2010	87,570	-49,075	'	-53,230	'	'	-14,735
Ending Balance, Shares at Dec. 31, 2010	87,500,000	'	'	'	'	'	'
Issuance of Common Stock , shares	2,182,290	'	'	'	'	'	'
Issuance of Common Stock , amount	2,182	1,358,258	'	'	'	'	1,360,440
Shares issued for Services, shares	75,000	'	'	'	'	'	'
Shares issued for Services, amount	75	7,425	'	'	'	'	7,500
Conversion of convertible note, shares	355,695	'	'	'	'	'	'
Conversion of convertible note, amount	356	70,782	'	'	'	'	71,139
Proceeds on share sales - 5BARz AG	'	75,840	'	'	'	'	75,840
Net loss	'	'	'	-781,147	'	'	-781,147
Minority Interest	'	'	'	'	528	'	528
Ending Balance, Amount at Dec. 31, 2011	90,183	1,463,231	0	-834,377	528	'	719,565
Ending Balance, Shares at Dec. 31, 2011	90,182,785	'	'	'	'	'	'
Issuance of Common Stock , shares	6,541,667	'	'	'	'	'	'
Issuance of Common Stock , amount	6,542	513,458	'	'	'	'	520,000
Shares issued for Services, shares	10,042,491	'	'	'	'	'	'
Shares issued for Services, amount	10,042	778,421	'	'	'	'	798,463
Stock option expense	'	7,113	'	'	'	'	7,113
Conversion of convertible note, shares	401,338	'	'	'	'	'	'
Conversion of convertible note, amount	401	11,599	'	'	'	'	12,000
Proceeds on share sales - 5BARz AG	'	203,230	'	'	'	'	203,230
Shares issued - Investement in CelLynx Group Inc, shares	1,250,000	'	'	'	'	'	'
Shares issued - Investement in CelLynx Group Inc, amount	1,250	248,750	'	'	'	'	250,000
Intangible assets, shares	9,000,000	'	'	'	'	'	'
Intangible assets, amount	9,000	1,791,000	'	'	'	'	1,800,000
Elimination of Cellynx investement in 5Barz	'	-1,800,000	'	'	'	'	-1,800,000
Net loss	'	'	'	-2,136,722	109,329	'	-2,027,393
Foreign Currency Gain	'	'	'	'	'	4,272	4,272
Other	'	'	'	'	10,273	'	10,273
Sale of non-controlling interest	'	'	'	'	10,531	'	10,531
Effect of CelLynx consolidation	'	'	'	'	583,333	'	583,333
Ending Balance, Amount at Dec. 31, 2012	117,418	3,226,802	0	-2,971,099	713,994	4,272	1,091,387
Ending Balance, Shares at Dec. 31, 2012	117,418,281	'	'	'	'	'	'
Beginning Balance, Amount at Dec. 28, 2012	'	'	'	'	'	'	'
Issuance of Common Stock , amount	20,000	'	'	'	'	'	'
Shares issued for Services, amount	112,500	'	'	'	'	'	'
Ending Balance, Amount at Dec. 31, 2012	117,418	3,226,802	0	-2,971,099	713,994	4,272	1,091,387
Ending Balance, Shares at Dec. 31, 2012	117,418,281	'	'	'	'	'	'
Shares cancelled, Shares	-1,600,000	'	'	'	'	'	'
Shares cancelled, Amount	-1,600	-78,400	'	'	'	'	-80,000
Issuance of Common Stock , shares	35,775,000	'	'	'	'	'	'
Issuance of Common Stock , amount	35,775	2,894,975	'	'	'	'	2,930,750
Shares issued for Services, shares	3,581,200	'	'	'	'	'	'
Shares issued for Services, amount	3,581	225,159	'	'	'	'	228,740
Stock option expense	'	592,622	'	'	'	'	592,622
Conversion of convertible note, shares	25,000	'	'	'	'	'	'
Conversion of convertible note, amount	25	4,975	'	'	'	'	5,000
Shares issued for Debt, shares	8,689,710	'	'	'	'	'	'
Shares issued for Debt, amount	8,690	763,751	'	'	'	'	772,441
Proceeds on share sales - 5BARz AG	'	91,276	'	'	'	'	91,276
Share price adjustment, shares	20,000	'	'	'	'	'	'
Share price adjustment, amount	20	-20	'	'	'	'	0
Net loss	'	'	'	-2,202,499	-94,101	'	-2,296,600
Foreign Currency Gain	'	'	'	'	'	24,962	24,962
Ending Balance, Amount at Dec. 31, 2013	163,909	7,721,140	'	-5,173,598	619,893	29,234	3,360,578
Ending Balance, Shares at Dec. 31, 2013	163,909,191	'	'	'	'	'	'
Beginning Balance, Amount at Dec. 29, 2013	'	'	'	'	'	'	'
Shares issued for Services, amount	71,750	'	'	'	'	'	'
Ending Balance, Amount at Dec. 31, 2013	$163,909	'	'	'	'	'	'
Ending Balance, Shares at Dec. 31, 2013	163,909,191	'	'	'	'	'	'

Organization_Going_Concern_and

Organization, Going Concern and Development Stage	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Organization, Going Concern and Development Stage	'
	Note 1 – Organization, Going Concern and Development Stage
	The Company was incorporated under the laws of the State of Nevada on November 14, 2008. The Company was originally named “Bio-Stuff” and was a designated shell corporation from inception to the date of acquisition of the 5BARz assets.
	In 2010 the Company changed its name to 5BARz International, Inc. and the Company acquired a set of agreements for certain intellectual property underlying the 5BARz™ products, and marketing rights. The 5BARz products are highly engineered wireless units referred to as “cellular network infrastructure devices”. The 5BARz™ device captures cell signal and provides a smart amplification and resend of that cell signal giving the user improved cellular reception in their home, office or while mobile. Pursuant to the agreements referred to above, the Company was engaged as the exclusive agent for the global sales and marketing of the 5BARz™ products. On March 29, 2012, 5BARz International, Inc. acquired a 60% controlling interest in CelLynx Group, Inc. and a 60% interest in the intellectual property underlying the 5BARz™ products.
	On November 6, 2011, the Company incorporated a subsidiary Company in Zurich, Switzerland called 5BARz AG which is a 94.3% held subsidiary at December 31, 2013. This entity has been granted the license for the marketing and distribution rights for 5BARz™ products in Germany, Austria and Switzerland. .
	These financial statements reflect the financial position for the Company and its subsidiary companies 5BARz AG, CelLynx Group Inc. and its wholly owned subsidiary CelLynx Inc. as at December 31, 2013. Results of operations for subsidiary Companies are reflected only from the date of acquisition of that subsidiary for the period indicated in the respective statement.
	Going concern
	The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is a development stage company and has not commenced planned principal operations. As shown in the accompanying consolidated financial statements, the Company has incurred recurring losses for the period from November 14, 2008 (date of inception) through December 31, 2013 of $5,158,370. The Company has negative cash flows from operations since inception of $3,601,301 and has an accumulated deficit of $5,173,598 at December 31, 2013. The Company has generated no revenues to date. The Company is seeking additional sources of equity or debt financing, and there is no assurance these activities will be successful. These factors raise substantial doubt about the Company’s ability to continue as a going concern and the Company’s continued existence is dependent upon adequate additional financing being raised to develop its sales and marketing program for the sales of 5BARz™ product and commence its planned operations.
	The accompanying consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.
	Development stage
	The Company is considered to be a development stage entity as defined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 915. The Company has been a development stage entity since November 14, 2008 its inception. The Company has not generated any revenue to date.

Summary_of_significant_account

Summary of significant accounting policies

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

'

Summary of significant accounting policies

'

Note 2 - Summary of significant accounting policies

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The accompanying consolidated financial statements include the accounts of 5BARz International Inc., and its 94.3% owned subsidiary, 5BARz AG, and it’s 60% owned subsidiary CelLynx Group, Inc. and that Company’s 100% owned subsidiary CelLynx, Inc. All intercompany accounts and transactions have been eliminated upon consolidation.

Cash

Cash and cash equivalents include cash in hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of one year or less.

Use of estimates

The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include impairment analysis for long lived assets, income taxes, litigation and valuation of derivative instruments. Actual results could differ from those estimates.

Concentration of credit risk

Cash includes deposits in accounts maintained at financial institutions.  Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash. The Company maintains balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for the banks located in the United States. As of December 31, 2013 and 2012, the Company did not have any deposits in excess of federally-insured limits.  To date, the Company has not experienced any losses in such accounts.

Research and Development Costs

Research and Development costs are charged to expense as incurred. The costs of materials and equipment that are required or constructed for research and development activities, and have alternative future uses (either in research and development, marketing or production), are classified as property and equipment and depreciated over their estimated useful lives.

Furniture & equipment

Furniture & equipment is recorded at historical cost and is depreciated using the straight-line method over their estimated useful lives.  The useful life and depreciation method are reviewed periodically to ensure that the depreciation method and period are consistent with the anticipated pattern of future economic benefits. Expenditures for maintenance and repairs are charged to operations as incurred while renewals and betterments are capitalized. Gains and losses on disposals are included in the results of operations. The useful life of the equipment is being depreciated over three to seven years.

Inventory

Inventories are carried at the lower of cost and net realizable value. Cost is determined using the weighted-average method.   As of December 31, 2013 the Company’s inventory included 1,000 units of Road Warrior cellular networks extenders.

Goodwill and other intangible assets

The Company accounts for goodwill and intangible assets in accordance with the accounting guidance which requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. The Accounting Standards Codification (“Codification”) requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment). Application of the goodwill impairment test requires judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value. Significant judgment is required to estimate the fair value of reporting units which includes estimating future cash flows, determining appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value and/or goodwill impairment.

When testing goodwill for impairment, the Company may assess qualitative factors for some or all of its reporting units to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment for some or all of our reporting units and perform a detailed quantitative test of impairment (step 1). If the Company performs the detailed quantitative impairment test and the carrying amount of the reporting unit exceeds its fair value, the Company would perform an analysis (step 2) to measure such impairment. In 2013, the Company first performed a qualitative assessment to identify and evaluate events and circumstances to conclude whether it is more likely than not that the fair value of the Company’s reporting unit is less than its carrying amount. Based on the Company’s qualitative assessments, the Company concluded that a positive assertion can be made from the qualitative assessment that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount. In accordance with the Codification, the Company reviews the carrying value of its intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group, if any, exceeds its fair market value. No impairment was deemed to exist as of December 31, 2013 and 2012.

Long-Lived Assets Subject to Amortization

The Company amortizes intangible assets with finite lives over their estimated useful lives and reviews them for impairment annually or whenever an impairment exists. The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. There were no long-lived assets impairment charges recorded during the years ended December 31, 2013 and 2012.

Revenue recognition

The Company's revenue recognition policies are in compliance with ASC Topic 605, “Revenue Recognition.”  Revenue is recognized at the date of shipment to customers, and when the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured.

Foreign currency translation

Transactions in foreign currencies have been translated into US dollars using the temporal method. The functional currency of the Company’s subsidiary 5BARz AG, is its local currency (Swiss Franc – CHF). Under this method, monetary assets and liabilities are translated at the year-end exchange rate. Non-monetary assets have been translated at the historical rate of exchange prevailing at the date of the transaction. Expenses have been translated at the exchange rate at the time of the transaction. Realized and unrealized foreign exchange gains and losses are included in operations.

Fair value of financial instruments

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities, approximate fair value due to the short-term nature of these instruments.

Fair value is defined as an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

•

Level 1. Quoted prices in active markets for identical assets or liabilities.

•

Level 2. Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

•

Level 3. Significant unobservable inputs that cannot be corroborated by market data.

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the assets that are measured at fair value on a recurring basis.

Consolidated

Quoted Prices in Active Markets for Identical Assets or Liabilities

Quoted Prices for Similar Assets or Liabilities in Active Markets

Significant

Balance Sheet

(Level 1)

(Level 2)

Unobservable

Inputs

(Level 3)

Derivative Liabilities:

31-Dec-13

$

60,018

$

—

$

—

$

60,018

31-Dec-12

$

—

$

—

$

—

$

—

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

31-Dec-13

31-Dec-12

Beginning balance

$

—

$

—

Aggregate fair value of conversion feature upon issuance

57,995

469,332

Change in fair value of derivative liabilities

2,023

(469,332

)

Ending balance

$

60,018

$

—

The derivative conversion feature liabilities are measured at fair value using the Black-Scholes pricing model and are classified within Level 3 of the valuation hierarchy. The significant assumptions and valuation methods that the Company used to determine fair value and the change in fair value of the Company’s derivative financial instruments are provided below:

31-Dec-13

31-Dec-12

Stock price

$

0.25

$

0.05

Volatility

211

%

240

%

Risk-free interest rate

0.04

%

0.04

%

Dividend yield

0

%

0

%

Expected life

0.002 years

0.02 years

Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivate liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, which reports to the Chief Financial Officer, determines its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department with support from the Company’s consultants and which are approved by the Chief Financial Officer.

Level 3 financial liabilities consist of the derivative liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.

The Company uses the Black-Scholes option valuation model to value Level 3 financial liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as, volatility.

As of December 31, 2013 there were no transfers in or out of Level 3 from other levels in the fair value hierarchy.

Derivative Instruments

The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging”. The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liability at the fair value of the instrument on the reclassification date.

Stock-Based Compensation

The Company records stock-based compensation in accordance with ASC Topic 718, “Compensation – Stock Compensation.” ASC 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee’s requisite service period. Under ASC 718, the Company’s volatility is based on the historical volatility of the Company’s stock or the expected volatility of similar companies. The expected life assumption is primarily based on historical exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

The Company uses the Black-Scholes option-pricing model which was developed for use in estimating the fair value of options. Option-pricing models require the input of highly complex and subjective variables including the expected life of options granted and the Company’s expected stock price volatility over a period equal to or greater than the expected life of the options. Because changes in the subjective assumptions can materially affect the estimated value of the Company’s employee stock options, it is management’s opinion that the Black-Scholes option-pricing model may not provide an accurate measure of the fair value of the Company’s employee stock options. Although the fair value of employee stock options is determined in accordance with ASC 718 using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/seller market transaction.

The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

Income taxes

The Company accounts for income taxes in accordance with ASC Topic 740, “Income Taxes.” ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized.  Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company is open for examination for the years 2009, 2010, 2011, 2012 and 2013. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the period incurred.  No significant penalties or interest relating to income taxes have been incurred during the years ended December 31, 2013 and 2012.

Net loss per share

The Company reports loss per share in accordance with the ASC Topic 260, “Earnings Per Share.”, which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation.  In the accompanying financial statements, basic earnings per share of common stock is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants. These potentially dilutive securities of 49,855,171 and 8,540,000, respectively were not included in the calculation of loss per common share for the years ended December 31, 2013 or 2012 because their effect would be anti-dilutive. The weighted average number of shares outstanding does not include reciprocal shareholdings, held by the Company’s subsidiary, CelLynx Group, Inc. which is reflected as a reduction in capital in excess of par value on the Company’s balance sheet.

Recent Accounting Pronouncements

In July 2012, the FASB issued ASU 2012-02, “Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment."  This ASU simplifies how entities test indefinite-lived intangible assets for impairment which improve consistency in impairment testing requirements among long-lived asset categories. These amended standards permit an assessment of qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. For assets in which this assessment concludes it is more likely than not that the fair value is more than its carrying value, these amended standards eliminate the requirement to perform quantitative impairment testing as outlined in the previously issued standards. The guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s consolidated financial position and results of operations.

In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”).  The amendment requires disclosure of information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, disclosure is required, either on the face of the statement where net income is presented or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail about those amounts. The new requirements are effective for public companies in interim and annual reporting periods beginning after December 15, 2012. The adoption of ASU 2013-02 as of January 1, 2013 did not have an impact on the Company's consolidated financial statements.

The FASB has issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carry-forward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. For nonpublic entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The Company has not yet determined the effect of the adoption of this standard and it is expected to have a material impact on the Company’s consolidated financial position and results of operations.

FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2013 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2013 or 2012, and it does not believe that any of those pronouncements will have a significant impact on our consolidated financial statements at the time they become effective.

Furniture_and_Equipment

Furniture and Equipment	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Furniture and Equipment	'
	Note 3 – Furniture & equipment
	Furniture & Equipment consisted of the following at December 31, 2013 and December 31, 2012:
			31-Dec-13			31-Dec-12
	Office furniture and equipment		$	70,804		$	14,532
	Research and development equipment (i)			169,350			-
	Leasehold improvements			6,940			-
				247,094			14,532
	Accumulated amortization & depreciation			(21,111	)		-10,126
	Furniture & equipment net		$	225,983		$	4,406
	During the year ended December 31, 2013 the Company incurred amortization and depreciation expense of $10,985, (2012 - $1,451), and $15,558 from November 14, 2008 (date of inception) to December 31, 2013.
		(i)	The research and development equipment was subject to the terms of a capital lease agreement. (See Note 9)

Long_lived_assets_and_goodwill

Long lived assets and goodwill subject to amortization	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Intangible assets and goodwill	'
	Note 4 – Long lived assets subject to amortization
	Intangible assets are comprised of technology, trademarks and license rights which are recorded at cost. Patents and trademarks are amortized on a straight-line basis over a period not to exceed 20 years and 10 years, respectively. License rights are amortized over the period of the respective license agreement.
				31-Dec-13			31-Dec-12
	Technology		$	3,015,794		$	3,015,794
	Marketing and distribution agreement			370,000			370,000
	Trademarks			264			264
	License rights			1,348			1,348
				3,387,406			3,387,406
	Accumulated amortization			-			-
	Technology and other intangibles, net		$	3,387,406		$	3,387,406
	During the years ended December 31, 2013 and 2012 no amortization has been recorded on technology and other intangibles. The intangible assets will commence amortization with the initial commercial production (2014) of products incorporating the related technology. The Company’s estimated technology amortization over the next five years is expected to be $887,000.
	Marketing and distribution agreement will also commence amortization when the Company delivers its first product in 2014.
	The estimated amortization of intangible assets for the five years ended December 31, 2018 and thereafter is as follows:
	For the years ended
	December 31,						Marketing and		Trademark & license
			Total		Technology		distribution agreement		agreements
	2014	$	251,722	$	177,400	$	74,000	$	322
	2015		251,722		177,400		74,000		322
	2016		251,722		177,400		74,000		322
	2017		251,722		177,400		74,000		322
	2018		251,724		177,400		74,000		324
	Future years		2,128,794		2,128,794		-		-
		$	3,387,406	$	3,015,794	$	370,000	$	1,612

Goodwill

Goodwill	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill	'
	Note 5 - Goodwill
	The changes in the carrying amount of goodwill for the years ended December 31, 2013 and December 31, 2012 is as follows:
			31-Dec-13		31-Dec-12
	Goodwill – beginning of year	$	1,140,246	$	-
	Acquisition of CelLynx Group, Inc.		-		556,913
	Fair value of non-controlling interest		-		583,333
	Goodwill – end of year	$	1,140,246	$	1,140,246

Income_taxes

Income taxes	12 Months Ended
	Dec. 31, 2013
Schedule of Investments [Abstract]	'
Income taxes	'
	Note 6 - Income taxes:
	The domestic and foreign components of income (loss) before income taxes from continuing operations are as follows:
		31-Dec-13			31-Dec-12
	Domestic	$	(2,251,545	)	$	(1,882,912	)
	Foreign		(45,055	)		(144,481	)
	Loss from continuing operation before	$	(2,296,600	)	$	(2,027,393	)
	provision for income taxes
	The income tax provision (benefit) consists of the following:
		31-Dec-13			31-Dec-12
	Foreign
	Current	$	0		$	0
	Deferred		(9,912	)		(46,159	)
	US federal
	Current		0			0
	Deferred		(604,970	)		(980.972	)
	State & local
	Current		0			0
	Deferred		(214,066	)		(84,897	)
	Total		(828,948	)		(1,112,028	)
	Change in valuation allowance		828,948			1,112,028
	Income tax provision (benefit)	$	0		$	0
	The provision (benefit) for income taxes using the statutory federal tax rate as compared to the Company’s effective tax rate is summarized as follows:
		31-Dec-13			31-Dec-12
	US federal statutory income tax rate (benefit)		(34.0	%)		(34.0	%)
	State income taxes		(5.8	%)		(2.3	%)
	Fair value of beneficial conversion feature		1	%		(7.5	%)
	Acquired deferred balances		0	%		(11.2	%)
	Stock based compensation		10.4	%		0	%
	Other permanent differences		0.5	%		0.1	%
	Change in valuation allowance		27.9	%		54.9	%
	Effective rate		0	%		0	%
	The Company’s deferred tax assets (liabilities) consisted of the effects of  temporary differences attributable to the following:
		31-Dec-13			31-Dec-12
	Deferred tax assets
	Net operating loss carryovers	$	2,077,660		$	1,261,422
	R&D credit		66,017			0
	Accrued compensation		202,375			167,355
	Stock-based compensation		2,833			2,833
	Total deferred tax assets		2,348,886			1,431,610
	Valuation allowance		(2,163,259	)		(1,334,310	)
	Deferred tax asset, net of valuation allowance		185,627			97,300
	Deferred tax liabilities
	Fixed asset depreciation		(14,024	)		(170	)
	Intangible asset amortization		(171,602	)		(97,130	)
	Total deferred tax liabilities		(185,627	)		(97,300	)
	Net deferred tax asset (liability)	$	0		$	0
	As of December 31, 2013, the Company had approximately $5,075,000 and $2,950,000 of U.S. federal and state net operating loss carryovers (“NOL’s”), respectively, to offset future taxable income. As of December 31, 2012, the Company had approximately $3,375,000 and $1,159,000 of U.S. federal and state NOL’s, respectively, to offset future taxable income. The U.S. federal and state net operating loss carryovers begin expiring in 2025. In accordance with section 382 of the Internal Revenue Code, deductibility of the Company’s U.S. net operating loss carryovers may be subject to an annual limitation in the event of a change of control. Management has performed a preliminary evaluation as to whether a change in control has taken place, and has concluded that there was a change of control with respect to the NOL’s of CelLynx Group, Inc. when the Company acquired its 60% ownership interest in March 2012.
	Therefore, the NOL’s of CelLynx Group Inc. will be subject to an annual limitation of approximately $8,700 as determined under the regulations. Due to the annual limitation, management has determined that $8,600,000 of the NOL’s of CelLynx Group, Inc. will expire unused and has reduced the related deferred tax asset accordingly.
	The Company has not filed its tax return for the tax years 2011 (CelLynx), 2012 and 2013. The net operating losses and tax credit from those years will not be available until the Company files the tax returns.
	In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. After consideration of all of the information available, Management believes that significant uncertainty exists with respect to future realization of the deferred tax assets and has therefore established a full valuation allowance for all periods. For the years ended December 31, 2013 and 2012, the change in the valuation allowance was $828,949 and $1,334,310, respectively.
	The Company evaluated the provisions of ASC 740 related to the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. ASC 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as "unrecognized benefits." A liability is recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise's potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740.
	Interest costs related to unrecognized tax benefits are required to be calculated (if applicable) and would be classified as "Interest expense, net" in the statements of operation. Penalties would be recognized as a component of "General and administrative expenses."
	No interest or penalties were recorded during the year ended December 31, 2013 and December 31, 2012. As of December 31, 2013 and December 31, 2012 no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.
	The Company files U.S. federal and state income tax returns. These tax returns are subject to examination by tax authorities for years beginning in December 31, 2009.  5BARz AG files foreign tax returns in Switzerland. These tax returns are subject to examination by tax authorities for years beginning in 2011.
	Foreign earnings are considered to be indefinitely reinvested; accordingly, no provision for US federal and state income taxes has been provided thereon. Upon repatriation of earnings, in the form of dividends or otherwise, the Company would be subject to both US income taxes (subject to an adjustment for foreign tax credits) and withholding taxes payable to the various foreign countries. Determination of the amount of unrecognized deferred US income tax liability is not practicable due to recurring losses; however, unrecognized foreign tax credit carryforwards would be available to reduce some portion of the US liability.

Cumulative_Sales_of_Stock

Cumulative Sales of Stock	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Common Stock	'
	Note 7 - Cumulative sales of stock
	Since its inception, we have issued shares of common stock as follows:
	On November 14, 2008, the Companies Directors authorized the issuance of 7,100,000 founder shares at par value of $0.001. These shares are restricted under rule 144 of the Securities Exchange Commission.
	On various days in December 2008, our Directors authorized the issuance of 1,776,100 shares of common stock at a price of $0.01 per share as fully paid and non-assessable to the subscriber. These shares are not restricted and are free trading.
	On November 15, 2010, our Directors initiated a forward stock split of 18:1 and increased the authorized shares from 100,000,000 to 250,000,000
	On December 30, 2010, the Directors approved the cancellation of 87,800,000 shares of common stock.
	On December 31, 2010, the Directors issued 15,600,000 shares in conjunction with the acquisition of certain assets, more fully described in Note 7.
	On January 10, 2011 the Company issued 300,000 shares of common stock at a price of $1.00 per share for aggregate proceeds of $300,000.
	On January 15, 2011 the Company issued 200,000 shares of common stock at a price of $1.00 per share for aggregate proceeds of $200,000.
	On March 9, 2011 the Company issued 150,000 shares of common stock at a price of $1.00 per share for aggregate proceeds of $150,000.
	On April 4, 2011 the Company issued 350,000 shares of common stock at a price of $1.00 per share for aggregate proceeds of $350,000.
	On April 7, 2011 the Company issued 200,000 shares of common stock at a price of $1.00 per share for aggregate proceeds of $200,000.
	On June 3, 2011 the Company issued 5,000 shares of common stock at a price of $0.70 per share for aggregate proceeds of $3,500.
	On July 18, 2011 the Company issued 25,000 shares of common stock at a price of $1.00 per share for aggregate proceeds of $25,000.
	On July 21, 2011 the Company issued 69,610 shares of common stock at a price of $0.20 per share for aggregate proceeds of $13,922.
	On July 24, 2011 the Company issued 40,000 shares of common stock at a price of $0.50 per share for aggregate proceeds of $20,000.
	On October 20, 2011 the Company issued 37,500 shares of common stock at a price of $0.20 per share for aggregate proceeds of $7,500
	On November 8, 2011 the Company issued 200,000 shares of common stock at a price of $0.15 per share for aggregate proceeds of $30,000.
	On December 7, 2011 the Company issued 75,000 shares of common stock at a price of $0.10 per share for services provided in the amount of $7,500.
	On December 15, 2011 the Company issued 455,180 shares of common stock at a price of $0.10 per share for aggregate proceeds of $45,518.
	On December 1, 2011 the Company issued 355,695 shares of common stock at a price of $0.20 per share for conversion of a Convertible Debenture Agreement, dated August 15,2011 for a principal amount of Fifty Thousand Euros (€50,000), which bears interest at a rate of 8.5%. The aggregate proceeds amounted to $67,513.
	On December 19, 2011 the Company issued 150,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $15,000.
	In December 2011, 5BARz AG sold 21,000 common shares with a par value of 0.01 per share, at a price of CHF 3.00 ($3.26 US) per share, for aggregate proceeds of CHF 63,000 (US – $75,840). The proceeds received have been credited to additional paid in capital in these consolidated financial statements.
	On January 12, 2012 the Company issued 300,000 shares of common stock at a price of $0.10 per share for services for aggregate proceeds of $30,000.
	On February 1, 2012 the Company issued 1,500,000 shares of common stock at a price of $0.10 per share for services for aggregate proceeds of $150,000.
	On February 1, 2012 the Company issued 50,000 shares of common stock at a price of $0.10 per share for services for aggregate proceeds of $5,000.
	On February 7, 2012 the Company issued 500,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $50,000.
	On February 29, 2012 the Company issued 100,000 shares of common stock for services at a price of $0.4799 per share for aggregate proceeds of $47,990.
	On February 29, 2012 the Company issued 200,000 shares of common stock for services at a price of $0.10 per share for aggregate proceeds of $20,000.
	On March 6, 2012 the Company issued 433,334 shares of common stock at a price of $0.12 per share for aggregate proceeds of $52,000.
	On March 7, 2012 the Company issued 150,000 shares of common stock at a price of $0.12 per share for aggregate proceeds of $18,000.
	On March 20, 2012 the Company issued 333,334 shares of common stock at a price of $0.15 per share for aggregate proceeds of $50,000.
	On March 22, 2012 the Company issued 170,000 shares of common stock at a price of $0.15 per share for aggregate proceeds of $25,500.
	On March 26, 2012 the Company issued 50,000 shares of common stock at a price of $0.12 per share for aggregate proceeds of $6,000.
	On March 29, 2012 the Company issued 9,000,000 shares of common stock at a price of $0.20 per share in payment to CelLynx Group, Inc. for a 60% for aggregate proceeds of $1,800,000. The shares were issued to acquire the 5BARz cellular technology rights.
	On March 29, 2012 the Company issued 1,250,000 shares of 5BARz common stock at a price of $0.20 per share for aggregate proceeds of $250,000, plus $170,000 cash, in payment to two founders of CelLynx Group Inc. for 63,412,638 common shares of CelLynx Group, Inc.
	On April 2, 2012 the Company issued 250,000 shares of common stock for services, at a price of $0.12 per share for an aggregate value of $30,270.
	On April 18, 2012 the Company issued 100,000 shares of common stock at a price of $0.15 per share for aggregate proceeds of $15,000.
	On April 30, 2012 the Company issued 125,000 shares of common stock at a price of $0.12 per share for services for an aggregate value of $14,977.
	On April 30, 2012 the Company issued 66,667 shares of common stock at a price of $0.15 per share for services for an aggregate value of $10,000.
	On May 3, 2012 the Company issued 80,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $8,000.
	On May 14, 2012 the Company issued 20,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $2,000.
	On June 12, 2012 the Company issued 95,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $9,500.
	On June 21, 2012 the Company issued 2,150,000 shares of common stock at a price of $0.10 per share for services for an aggregate value of $212,685.
	On June 27, 2012 the Company issued 50,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $5,000.
	On July 9, 2012 the Company issued 520,000 shares of common stock at a price of $0.10 per share for aggregate proceeds of $52,000.
	On July 20, 2012 the Company issued 250,000 shares of common stock at a price of $0.20 per share for services for an aggregate value of $50,000.
	On August 10, 2012 the Company issued 500,000 shares of common stock at a price of $0.05 per share for aggregate proceeds of $25,000.
	On August 14, 2012 the Company issued 500,000 shares of common stock at a price of $0.05 per share for aggregate proceeds of $25,000.
	On August 14, 2012 the Company issued 140,000 units at a price of $0.05 per unit for aggregate proceeds of $7,000. Each unit is comprised of one share and one warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term.
	On September 5, 2012 the Company issued 100,000 units at a price of $0.05 per unit for aggregate proceeds of $5,000. Each unit is comprised of one share and one warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term.
	On September 10, 2012 the Company issued 401,338 shares of common stock at a price of $0.0299 per share as partial conversion of a note payable in settlement of $12,000 due under that note.
	On September 14, 2012 the Company issued 300,000 shares of common stock at a price of $0.05 per share for aggregate proceeds of $15,000.
	On October 12, 2012 the Company issued 300,000 units at a price of $0.05 per unit for aggregate proceeds of $15,000. Each unit is comprised of one share and one warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term.
	On October 26, 2012 the Company issued 100,000 shares of common stock at a price of $0.05 per share for aggregate proceeds of $5,000.
	On December 7, 2012 the Company issued 3,300,824 shares of common stock at a price of $0.05 per share, for services with a total value of $165,041.
	On December 12, 2012 the Company issued 400,000 units at a price of $0.05 per unit for aggregate proceeds of $20,000. Each unit is comprised of one share and one warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term.
	On December 17, 2012 the Company issued 1,200,000 units at a price of $0.05 per unit for aggregate proceeds of $60,000. Each unit is comprised of one share and one warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term.
	On December 31, 2012 the Company issued 2,250,000 shares for services at a price of $0.05 per share, for a total value of $112,500.
	On January 25, 2013 the Company issued 100,000 shares and warrants in settlement of accounts payable for services rendered in the amount of $5,000.
	On February 12, 2013 the Company issued 125,000 shares of common stock at a price of $0.06 per share as partial settlement of $7,500 due under a note payable.
	On February 15, 2013 the Company issued 1,440,000 shares of common stock at a price of $0.05 per share, for services with a total value of $72,000.
	On February 26, 2013 the Company issued 250,000 shares of common stock at a price of $0.04 per share, in settlement of accounts payable with a total value of $10,000.
On February 26, 2013 the Company issued 91,780 shares of common stock at a price of $0.05 per share, in settlement of accounts payabe, with a total value of $4,589.
On March 1, 2013 the Company issued 175,000 shares of common stock at a price of $0.05 per share, for services with a total value of $8,750.
On March 1, 2013 the Company issued 600,000 shares of common stock at a price of $0.05 per share, for aggregate proceeds of $30,000.
On March 17, 2013 the Company issued 513,827 shares of common stock at a price of $0.05 per share, in settlement of accounts payable with a total value of $25,691.
On March 31, 2013 the Company issued 100,000 shares of common stock at a price of $0.05 per share, in settlement of accounts payable with a total value of $5,000.
During the period from January 4, 2013 to June 21, 2013 the Company issued 11,735,000 units at a price of $0.05 per unit for aggregate proceeds of $586,750. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.20 per share acquired, with a two year warrant term.
On April 1, 2013 the Company issued 425,000 shares and warrants, with a two year term and $0.20 exercise price, in settlement of accounts payable with a total value of $21,250.
On April 10, 2013 the Company issued 600,000 shares of common stock at a price of $0.05 per share, for aggregate proceeds of $30,000.
On May 15, 2013 the Company issued 200,000 shares of common stock at a price of $0.05 per share for services with a total value of $10,000.
On May 23, 2013 the Company issued 200,000 shares and warrants, with a two year term and $0.20 exercise price, in settlement of accounts payable with a total value of $10,000.
On May 28, 2013 the Company issued 100,000 shares of common stock at a price of $0.05 per share, for debt with a total value of $5,000.
On July 1, 2013 the Company issued 331,200 shares and warrants, with a two year term and $0.20 exercise price, for services with a total value of $66,240.
During the period July 25, 2013 to March 6, 2014 the Company issued 29,215,000 units at a price of $0.10 per unit for aggregate proceeds of $2,921,500. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.30 per share acquired, with a two year term on the attached warrant. The private placement includes proceeds of $637,500 which was raised subsequent to December 31, 2013, and is not included in the balance sheet at December 31, 2013.
On November 15, 2013 the Company issued 25,000 shares on partial conversion of a note payable at a price of $0.20 per share for a total debt reduction of $5,000.
During the period September 5, 2013 to November 18, 2013 the Company issued 6,044,103 units at a price of $0.10 per unit in order to settle debts, for proceeds of $604,411. Each is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.30 per share acquired, with a two year term on the attached warrant.
On December 31, 2013 the Company issued 740,000 shares and warrants, with a two year term and a $0.30 exercise price for accounts payable with a total value of $74,000.
On December 31, 2013 the Company issued 1,435,000 shares and warrants, with a two year term and a $0.20 exercise price for services, with a total value of $71,750.

Asset_Acquisiton_Agreement

Asset Acquisiton Agreement	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Asset Acquisiton Agreement	'
	Note 8 - Asset acquisition agreement:
	On December 31, 2010, the Company entered into three agreements as follows;
	(i)                 An “Amended and Restated Master Global Marketing and Distribution Agreement.”
	(ii)               An asset purchase agreement
	(iii)             A line of credit agreement and security agreement
	These agreements with CelLynx Group, Inc. provide for the exclusive global marketing and distribution of the 5BARz™ line of products and related accessories and a 50% ownership interest in the 5BARz™ intellectual property. In addition, a revolving line of credit facility has been made available to CelLynx.
	On March 29, 2012, the Company and CelLynx Group Inc. entered into an agreement which provided several amendments to the agreement referred to above. As a result of those amendments, the following arrangements between the Companies were established;
		i.            5BARz International, Inc. acquired a 60% interest in the patents and trademarks held by CelLynx Group Inc., referred to as the “5BARz™” technology. That interest in the technology was acquired for proceeds comprised of 9,000,000 shares of the common stock of the Company, valued at the date of acquisition at $0.20 per share or $1,800,000 USD. The acquisition agreement also clarified that the ownership interest in the intellectual property does represent that proportionate interest in income earned from the intellectual property.
		ii.            The Company agreed to make available to CelLynx Group, Inc a revolving line of credit facility in the amount of $2.2 million dollars of which $730,879 has been advanced as of December 31, 2012. This revolving line of credit facility expires on October 5, 2013. Under the terms of the line of credit facility, the Company has the right to convert amounts due under the facility into common stock of CelLynx, at a conversion rate which is the lesser of a fixed conversion rate of $0.00015 per share or a variable rate which is calculated at 25% of the average lowest three closing bid prices of the CelLynx Group, Inc. common stock for a period which is ten (10) days prior to the date of conversion. This conversion rate was established previously by other parties that have funded CelLynx, and is being matched by 5BARz. At December 31, 2012, the Company had converted $139,200 of the amount due under the revolving line of credit facility for 854,745,971 shares of the capital stock of CelLynx Group, Inc. CelLynx is a consolidated subsidiary of 5BARz International Inc., since March 29, 2012.
		iii.            Pursuant to the Master Global Marketing and Distribution agreement between 5BARz International Inc and Cellyx Group, Inc., the registrant was obligated to pay to CelLynx Group, Inc a royalty fee amounting to 50% of the Company’s Net Earnings, from products or license arrangements related to the 5BARz™ technology, in a ratio equal to the CelLynx proportionate interest in that technology. That fee would be paid on a quarterly basis, payable in cash or immediately available funds and shall be due and payable not later than 45 days following the end of each calendar quarter of the year. The asset acquisition agreement amendment referred to herein specified that the royalties would be paid in relation to the ownership of the intellectual property. In addition as a result of the recent acquisition of a 60% interest in CelLynx Group, Inc. by the registrant, this royalty item is an intercompany transaction which in the future will be eliminated upon consolidation in financial reporting of the consolidated financial results of 5BARz International Inc. and subsidiaries.

Convertible_Securities

Convertible Securities	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Convertible Securities	'
	Note 9 – Convertible Securities
	Convertible Promissory Notes
			Unpaid		Note	Unpaid		Balance		Balance
			Note Principal		Terms	Interest & penalty		31-Dec-13		31-Dec-12
	Issue Date
	5BARz International, Inc.
	27-Feb-12		$	-	(a)	$	-	$	-	$	40,832
	3-May-12			-	(b)		-		-		67,131
	18-Sep-12			-	(c)		-		-		20,712
	3-Feb-12			-	(d)				-		207,500
	8-Jun-12			50,000	(d)		53,997		103,997		100,000
	17-Dec-12			80,000	(e)		6,645		86,645		—
	8-Jan-13			147,428	(f)		6,589		154,017		—
	Notes payable – 5BARz International Inc.		$	277,428		$	67,231	$	344,659	$	436,175
	CelLynx Group Inc.
	November. 10, 2007		$	-	(g)	$	-	$	-	$	316,693
	5-Apr-11			-	(h)		-		-		98,613
	5-Jan-12			-	(i)		-		-		80,438
	24-May-12			19,500	(j)		18,322		37,822		42,433
	12-Sep-12			12,500	(k)		15,202		27,702		19,202
	Notes payable CelLynx Group, Inc.		$	32,000		$	33,524	$	65,524	$	557,379
	Total		$	309,428		$	100,755	$	410,183	$	993,554
		(a)	On February 27, 2012, 5BARz International Inc., completed a transaction pursuant to a Promissory Note agreement (the “February 27, 2012 Note”), through which the Company borrowed $37,500. The Note bears interest at a rate of 8%, and is due on November 29, 2012, (the “Due Date”).  The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible into common stock at a variable conversion price equal to 55% of the average of the three lowest closing bid prices for the Company’s common stock for a period of 10 days prior to the date of notice of conversion. On September 10, 2012, the Company redeemed $12,000 payable on that note, by the issuance of 401,338 common shares at a price of $0.0299 per share. On January 4, 2013 the Company repaid $25,000 leaving a balance due of $2,771. That amount was paid in full on October 11, 2013 and the note was cancelled.
		(b)	On May 3, 2012, 5BARz International Inc., completed a transaction pursuant to a Promissory Note agreement (the “May 3, 2012 Note”), through which the Company borrowed $42,500. The proceeds were received by the Company on May 24, 2012. The Note bears interest at a rate of 8%, and is due on February 3, 2013, (the “Due Date”).  The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible into common stock at the option of the holder at a variable conversion price equal to 55% of the average of the three lowest closing bid prices for the Company’s common stock for a period of 10 days prior to the date of notice of conversion. The note principal and accrued interest was paid in full on October 11, 2013 and the note was cancelled.
		(c)	On September 18, 2012, the Company completed a transaction pursuant to a Promissory Note agreement (the “September 18, 2012 Note”), through which the Company borrowed $13,500. The Note bears interest at a rate of 8%, and is due on March 17, 2013, (the “Due Date”).  The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible at the option of the holder into common stock at a variable conversion price equal to 55% of the average of the three lowest closing bid prices for the Company’s common stock for a period of 10 days prior to the date of notice of conversion. The note principal and accrued interest was paid in full on October 11, 2013 and the note was cancelled.
		(d)	In January 2012, the Company negotiated potential agreements for a convertible debenture and an equity investment agreement with a private investment firm (La Jolla). On February 3, 2012 the investment firm advanced $100,000, and on June 8, 2013 they advanced $50,000 to the Company. As contemplated, the convertible debenture agreement provided that the investor could invest up to $500,000 and convert the principal and unpaid interest into a certain number of shares, 180 days from the date of the agreement. The equity investment agreement provided to Holder the right, from time to time during the term of the Agreement, to invest in the Company through the purchase of up to $5,000,000 of the Company’s Common Stock. Each purchase under this Agreement was to be made at 150% of the “Volume Weighted Average Price” (VWAP) on the day prior to the day the investment is made (the “Purchase Price”). Beginning on the date that is one hundred eighty (180) days following the Issue Date, Holder shall have the right to purchase Common Stock under this Agreement. Provided the VWAP is above $0.06, Holder shall purchase a minimum of $50,000 per month beginning two hundred ten (210) days from the Issue Date.
	On August 2, 2012 and August 13, 2012, the Company received conversion notices that materially conflict with the parties’ negotiations and the terms of the agreement. The Company offered to repay the amounts invested along with accrued interest and additional share compensation, but arrived at no settlement.
	On October 16, 2012, the investment firm filed a complaint in the federal court for the Northern District of California claiming breach of contract and seeking compensatory damages and alleged loss of profits of in excess of $2,500,000, based upon their $150,000 investment made under the putative agreements. La Jolla Cove Investors, Inc. v. 5BARz International, Inc., 3:12-CV-5333 (N.D. Cal.). On November 8, 2012, the Company filed an answer, affirmative defenses, and counterclaims, against the plaintiff. On January 3, 2013, the Company entered into a settlement agreement requiring payments in the aggregate amount of $300,000 yielding interest at 9%, and the issuance of 125,000 shares of the common stock of the Company. The Company issued the 125,000 shares on February 12, 2013. On March 13, 2013, an order granting entry of stipulated judgment was granted to La Jolla Cove Investors for payment by the Company of the $300,000 plus interest at 9%. During the year ended December 31, 2013 the Company repaid $220,000, leaving a balance of $103,997 payable at December 31, 2013. Subsequent to December 31, 2013 the Company paid $25,000 on February 7, 2014, leaving a residual balance due of $78,997.
		(e)	In December 2012, a shareholder purchased 1,600,000 common shares for $80,000. The Company included the shares in issued and outstanding shares as of December 31, 2012, but the investor never took possession of the shares. On January17, 2013, the security was amended to a convertible debenture with an 8% per annum yield and may be converted into common stock, 90 days after the inception of the agreement, at a price which is a 20% discount to market, but not less than $0.05 per share.  During the year ended December 31, 2013, interest of $6,645 was accrued on the convertible debenture. In connection with the convertible debt, the Company recorded $21,747 of derivative liability as of December 31, 2013.
		(f)	On January 8, 2013 the Company entered into a convertible debenture agreement with a consultant in settlement of $147,428 payable to that consultant for services rendered. The convertible debenture yields interest at 8% per annum and may be converted into common stock, 90 days after the inception of the agreement, at a price which is a 20% discount to market, but not less than $0.05 per share.  During year ended December 31, 2013, interest of $11,589 was accrued on the convertible debenture. In connection with the convertible debt the Company recorded $38,271 of derivative liability as of December 31, 2013. On November 15, 2013 the holder converted $5,000 of the amount due under the convertible debenture for 25,000 shares. At December 31, 2013 the principal and unpaid interest due was $154,017.
		(g)	On August 15, 2006, CelLynx, Inc. issued a secured promissory note (the “August 2006 Note”) for $250,000 to an unrelated entity “Holder”.  On November 10, 2007, the August 2006 Note was amended (the “Amended Note”).  At the date of the amendment, the Company was obligated to pay to the Holder $262,356 which represented the principal and accrued interest. In contemplation of the completion of the reverse merger, the Company and the holder reached an agreement whereby this Amended Note superseded the August 2006 Note.  The principal amount of the Amended Note is $262,356, is unsecured and bears interest at 4% per annum, computed on the basis of the actual number of days elapsed and a year of 365 days.  All unpaid principal, together with any then accrued but unpaid interest, shall be due and payable upon the earlier of (i) November 9, 2010 at the written request of the holder to the Company, or (ii) when, upon or after the occurrence of an event of default. The principal amount is convertible into 4.8% of the Company shares outstanding. On August 2, 2013 the Company entered into a settlement and release agreement with the holder of the unsecured promissory note, which required a payment by the Company on or before September 15, 2013 in the amount of $27,500, for the settlement of the full amount of the note payable in the principal amount of $262,356. On October 24, 2013, the parties agreed to settle the debt by issuance of 275,000 units at a price of $0.10 per unit with each unit comprised of one (1) common share of 5BARz and one share purchase warrant at $0.30, exercisable for a period of two years.
	At December 31, 2013 this promissory note along with accrued interest was paid in full.
		(h)	On April 5, 2011, CelLynx Group, Inc. entered into a Securities Purchase Agreement with a former director of Cellyx Group, Inc., in connection with the purchase of a Convertible Promissory Note. Pursuant to the convertible note agreement the former director loaned to CelLynx Group, Inc. the principal amount of $50,000. The Note bears interest at a rate of 8%, and was due on January 5, 2012. Pursuant to the terms of the note, the principal and accrued interest could have been converted into shares of the Company’s common stock, with the number of shares issuable determined by dividing the amount to be converted by the conversion price which is equal to 63% of the average of the three lowest trading prices of the Company’s common stock over the ten trading days prior to the date of the conversion. On November 8, 2013, the parties agreed to settle the note principal and accrued interest by issuance of 603,780 units at a price of $0.10 per unit with each unit comprised of one (1) common share of 5BARz and one share purchase warrant at $0.30, exercisable for a period of two years. At December 31, 2013, this note payable principal and accrued interest was paid in full.
		(i)	On January 5, 2012, CelLynx Group, Inc. issued a note in the amount of $50,000, by way of settlement of certain debts owed by the Company to Holder. The Note bears interest at a rate of 8%, and was due on July 3, 2012. Holder may convert principal and unpaid interest on the note into shares of the Company’s common stock, with the number of shares issuable determined to be the amount obtained by dividing the amount to be converted by the conversion price which is the lesser of $0.0013 per share or 63% of the average of the three lowest trading prices of the Company’s common stock over the ten trading days prior to the date of the conversion. On June 5, 2013 the Company entered into a settlement agreement with the holder of the convertible promissory note whereby it was agreed that provided that the Company made a payment of $35,000 on or before September 15, 2013, that the principal balance and accrued penalties and interest on the note and other accounts payable due to the creditor aggregating $170,000 will be settled in full. That cash payment was not made. On October 25, 2013 the parties agreed to settle the note principal and accrued interest and other payables aggregating $163,743 by issuance of 440,000 units at a price of $0.10 per unit with each unit comprised of one (1) common share of 5BARz and one share purchase warrant at $0.30, exercisable for a period of two years. At December 31, 2013, the note payable and accrued interest was paid in full.
		(j)	On May 24, 2012, CelLynx Group, Inc., completed a transaction pursuant to a Promissory Note agreement, through which the Company borrowed $37,500. The Note bears interest at a rate of 8%, and is due on November 24, 2012, (the “Due Date”).  The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible into common stock at a variable conversion price equal to 51% of the average of the three lowest closing bid prices for CelLynx Group, Inc’s common stock for a period of 10 days prior to the date of notice of conversion. The Company redeemed $18,000 payable on that note, by the issuance of CelLynx Group, Inc. common shares. As of December 31, 2013 the note is past due. The value of the derivative liability associated with this note at December 31, 2013 was immaterial. The note principal and accrued interest outstanding at December 31, 2013 was $37,822.
		(k)	On September 12, 2012, CelLynx Group, Inc., completed a transaction pursuant to a Promissory Note agreement, through which the Company borrowed $12,500. The Note bears interest at a rate of 8%, and is due on March 12, 2013, (the “Due Date”).  The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principal amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principal amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note and accrued interest are convertible into common stock at a variable conversion price equal to 51% of the average of the three lowest closing bid prices for CelLynx Group, Inc’s common stock for a period of 10 days prior to the date of notice of conversion. As of December 31, 2013 the note is past due. The value of the derivative liability associated with this note at December 31, 2013 was immaterial. The note principal and accrued interest outstanding at December 31, 2013 was $27,702.

Capital_Lease_Obligation

Capital Lease Obligation	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Capital Lease Obligation	'
	Note 10 – Capital Lease Obligation
	On November 1, 2013 the Company entered into a capital lease obligation for the acquisition of research and development equipment in San Diego, California. The lease requires a payment of $5,000 per month for thirty-six (36) months, representing minimum lease payments as follows;
	2014	$	60,000
	2015	$	60,000
	2016	$	50,000
	Total	$	170,000
	Interest (12%)	$	9,536
	Capitalized valuation of equipment	$	160,464
	During the year ended December 31, 2013 amortization expense of $7,056 was recorded on the R&D equipment (see Note 3).

Options_and_Warrants

Options and Warrants	12 Months Ended
	Dec. 31, 2013
Options And Warrants	'
Options and Warrants	'
	Note 11 – Options and Warrants
	Warrants – 5BARz International Inc.
	The following table summarizes the warrant activity to December 31, 2013:
		Number of		Weighted Average		Average Remaining
		Warrants		Exercise Price		Contractual Life
	Outstanding at December 31, 2012		2,140,000	$	0.2		2
	Granted		47,040,103	$	0.26
	Exercised		—		—
	Cancelled		1,600,000	$	0.2
	Outstanding at December 31, 2013		47,580,103	$	0.26		1.64
	Exercisable at December 31, 2013		47,580,103	$	0.26		1.64
	Options – 5BARz International Inc.
	At December 31, 2013, 5BARz International, Inc. has the following Options outstanding;
		Number of Options		Weighted Average Exercise Price		Weighted Average
						Remaining Contractual
						Life (years)
	Outstanding – December 31, 2012		—		—
	Granted		4,000,000		0.1		2.5
	Outstanding – December 31, 2013		4,000,000		0.1		2.5
	Exercisable- December 31, 2013		1,079,452		0.1		2.5
	Options – CelLynx Group, Inc.
	At December 31, 2013, CelLynx Group Inc. has the following Options outstanding;
		Number of Options		Weighted Average Exercise Price		Weighted Average
						Remaining Contractual
						Life (years)
	Outstanding – December 31, 2012		6,400,000		0.0008		2.5
	Cancelled		6,400,000		0.0008		2.5
	Granted		65,000,000		0.0002		4.6
	Outstanding – December 31, 2013		65,000,000		0.0002		4.6
	Exercisable- December 31, 2013		65,000,000		0.0002		4.6
	Warrants – CelLynx Group, Inc.
	The following table summarizes the warrant activity to December 31, 2012:
		Number of		Weighted Average		Average Remaining
		Warrants		Exercise Price		Contractual Life
	Outstanding at December 31, 2012		5,930,000	$	0.12
	Granted
	Exercised		—		—
	Expired		1,430,000		0.12
	Outstanding at December 31, 2013		4,500,000	$	0.96		1.15
	Exercisable at December 31, 2013		4,500,000	$	0.96		1.15

Related_Party_Transaction

Related Party Transaction	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Related Party Transaction	'
	Note 12 - Related party transactions:
	On December 30, 2010 the Company acquired by way of an assignment agreement all right title and interest in a set of agreements from a Company of which the President and Director is also the President and Director of the reporting Company. The proceeds to be paid for that assignment agreement was comprised of a note payable in the amount of $370,000, and the issuance of 15,600,000 shares of common stock.  During the year ended December 31, 2013 the Company paid $19,850 of principal and interest, in full satisfaction of the note. During the year ended December 3, 2013, consulting fees were paid to a corporation controlled by the President and Director of the Company in the amount of $71,000, December 31, 2012 – Nil.
	On September 18, 2013 and November 7, 2013 the Company paid $15,000 and $50,000 respectively to a consultant, pursuant to the terms of a promissory note. The note is non-interest bearing and due on demand. Subsequently, on November 21, 2013, that consultant became Chairman of the Board. On February 1, 2014, the promissory note was paid in full by offset of amounts due for unpaid consulting fees.

Investment_in_5BARz_AG

Investment in 5BARz AG	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Investment in 5BARz AG	'
	Note 13 – Investment in 5BARz AG
	On October 6, 2011, the Company incorporated a subsidiary Company under the laws of Switzerland, in the Canton of Zurich, called 5BARz AG. 5BARz AG issued 10,000,000 common shares of which 5,100,000 are held by the Company, 450,000 are held by officers and a consultant to the Company and 4,450,000 were held in escrow for resale, by an independent escrow agent under the control of the Company. 5BARz AG issued the shares with a stated or par value of CHF 0.01 per share for proceeds of CHF 100,000 (US - $108,752). During the year ended December 31, 2013, sales of those securities held in escrow aggregated 30,000 shares sold for proceeds of $90,000 CHF ($100,710 USD). At December 31, 2013 the Company holds a 94.3% controlling interest in 5BArz AG represented by 9,428,000 shares.
	On October 19, 2011, the registrant, 5BARz International Inc. entered into a Marketing and Distribution agreement with 5BARz AG, through which 5BARz AG holds the exclusive rights for the marketing and distribution of products produced under the 5BARz™ brand for markets in Switzerland, Austria and Germany. That agreement does not have a royalty payment requirement, and remains effective as long as 5BARz Ag is controlled by the Company. 5BARz Ag is a consolidated subsidiary of the Company in these financial statements.

Investment_in_CelLynx_Group_In

Investment in CelLynx Group, Inc.	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Investment in CelLynx Group, Inc.	'
	Note 14 – Investment in CelLynx Group, Inc.
	On January 7, 2011 the Company entered into a stock purchase agreement with two founding shareholders of CelLynx Group, Inc. to acquire in aggregate 63,412,638 shares of the capital stock of CelLynx Group, Inc. for total proceeds of $634,126. At that date the Company had paid $170,000 as a deposit made under that agreement. On March 29, 2012 the Company entered into a securities exchange agreement and settlement agreement with each of the two founding shareholders of CelLynx Group, Inc. whereby in addition to the $170,000 paid, the Company issued 1,250,000 shares of common stock of the issuer in exchange for the 63,412,638 shares of CelLynx Group, Inc. and mutual releases were signed between the parties releasing each from any further obligation.
	As provided in Note 7 above, on March 29, 2012, the Company converted $73,500 of convertible debt in CelLynx Group, Inc for the issuance of 350,000,000 shares in the capital stock of CelLynx Group, Inc. As a result, in combination with the shares acquired from existing shareholders referred to above, the registrant acquired a 60% controlling interest in CelLynx Group, Inc. and has accounted for that acquisition as a consolidate subsidiary of the registrant effective March 29, 2012.
	On March 29, 2012, the Company acquired a 60% interest in CelLynx Group, Inc. a Company based in California, which was the owner of the 5BARz™ intellectual property and is in the business of the development and commercialization of that technology. The objective of the acquisition is to integrate the global commercialization of the 5BARz™ technology and products, into a combined business and operating strategy. The purchase price, which was settled in cash, shares, and the settlement of convertible debt was $875,000, as follows;
	i.		Cash consideration paid		$	170,000
	ii.		1,250,000 common shares of the registrant issued at a market price of $0.20 per share			250,000
	iii.		Redemption of convertible debt for 350 million shares of CelLynx Group Inc. common stock			455,000	(a)
			Fair market value of consideration paid		$	875,000
		(a)	The valuation of the debt instrument with an embedded conversion feature is calculated at the face value of the debt instrument of $73,500 plus the intrinsic value attributable to the conversion of the debt instrument at a 75% discount to market, based upon the lowest 3 closing bid prices of the common stock for a period of 30 days prior to the date of conversions. That intrinsic valuation is calculated to be $ 381,500.
	The amounts recognized for each class of the acquiree’s assets and liabilities recognized at the acquisition date, March 29, 2012 are as follows;
	Description		Net book value of CelLynx Group, Inc. consolidated assets and liabilities				Acquisition			Valuation attributed to assets acquired
							Adjustments (i) (ii)
	Current assets		$	3,260						$	3,260
	Technology, trademarks, and license			44,718			$	1,155,282	(ii)		1,200,000
	Investment in 5BARz   (iii)			1,800,000							1,800,000
	Furniture and equipment			2,113							2,113
	Accounts payable and accruals			(1,752,628	)						(1,752,628	)
	Notes payable (net of discount)			(403,076	)						(403,076	)
	Accrued interest			(62,250	)						(62,250	)
	Derivative liability			(5,495,425	)			5,026,093	(i)		(469,332	)
	LOC payable – 5BARz (net)			(586,525	)			586,525	(i)		—
	Fair value non-controlling interest							(583,333	)		(583,333	)
	Totals		$	(6,449,813	)		$	6,184,567			(265,246	)
	Goodwill										1,140,246
	Purchase price									$	875,000
		(i)	In determining the fair value of assets acquired, the Company eliminated the convertible debt owed to 5BARz and the derivative liability attributed to that debt.
		(ii)	Fair value of technology, trademarks and license.
		(iii)	Eliminates in consolidation
	As of December 31, 2013, the Company had a 60% interest in CelLynx Group, Inc.
	Subsequent to the date of acquisition, 5BARz International Inc. converted amounts of debt due from CelLynx Group Inc.. On April 13, 2012 the company converted $7,700 of debt in exchange for 51,333,333 shares of CelLynx and on May 17, 2012 5BARz converted $58,500 dollars of debt due from CelLynx for 390,000,000 shares of CelLynx and on May 15, 2013 the Company converted $9,375 dollars of debt due from CelLynx for 375,000,000 shares of CelLynx Group, Inc.. As a result of these conversions, the Company maintained its equity interest in CelLynx Group, Inc. at 60%.
	Unaudited pro forma combined financial information
	The following presents the unaudited pro forma combined financial information, as if the CelLynx acquisition had occurred as of January 1:
			For the Year Ended December 31, 2012
	Revenues		$	0
	Net loss after non-controlling interest		$	(1,070,117	)
	Pro forma basic and diluted net loss per common share		$	(0.01	)
	Pro forma weighted average common shares outstanding – basic and diluted			97,833,528
	The pro forma combined results of operations are not necessarily indicative of the results of operations that actually would have occurred had the acquisition of CelLynx been completed as of January 1, 2012, nor are they necessarily indicative of future consolidated results.

Litigation

Litigation	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Litigation	'
	Note 15 - Litigation
	Prior to the Company’s investment in CelLynx, on July 19, 2010 certain claims for unpaid wages were filed against CelLynx, Inc. Judgements were obtained commencing in August 2011 for back wages by some of its former employees. Some of those claims have been partially paid and others were expected to be paid in the normal course of business or were to be otherwise defended. Those claims have now been incorporated into California Labor Commission awards in favor of those former employees. Those awards total approximately $263,000 depending on interest charges. It is the Company’s intention to pay these amounts.  As of December 31, 2013 the Company accrued $263,000 in its financial statements.
	On October 16, 2012, a complaint was filed in the federal court for the Northern District of California against 5BARz International Inc. and does 1 through 10, claiming breach of contract and seeking compensatory damages and alleged loss of profits of in excess of $2,500,000, based upon a $150,000 investment made by LA Jolla Cove Investors under certain putative agreements. La Jolla Cove Investors Inc. v. 5BARz International, Inc., 3:12-CV-5333 (N.D. Cal.). On January 3, 2013, the Company and La Jolla Cove Investors, Inc. entered into an agreement for the settlement of the lawsuit for proceeds of $300,000 plus accrued interest from the date of the settlement agreement at a rate of 9%, plus the delivery of 125,000 shares of the common stock of the Company. On January 13, 2013 a stipulation dismissing action without prejudice and without award of attorney’s fees or costs was entered. On March 8, 2013 as a result not meeting the stipulated payment schedule, La Jolla Cove was awarded a judgment in the amount of $300,000 plus accrued interest at a rate of 9% from the date of the settlement agreement. During the year ended December 31, 2013, the Company issued the 125,000 shares and made payments aggregating $220,000. Notes payable reflected in the consolidated financial statements at December 31, 2013 include $103,997 of unpaid principal and interest remaining outstanding on this claim.
	On March 22, 2013 a complaint was filed in the Supreme Court of the State of New York, County of Nassau against 5BARz International Inc, Daniel Bland and James Vandeberg, by Asher Enterprises, Inc. claiming repayment of three Promissory notes in the principal amount of $81,000, penalties and interest. Asher Enterprises, Inc. vs. 5BARz International Inc.., Daniel Bland and James Vandeberg 13-003472(County of Nassau) The claims allege that damages in the amount of the greater of; (i) 200% x $81,000, the remaining outstanding principal amount of the Note, together with accrued and unpaid interest in the unpaid principal amount of the Notes, plus default interest; or (ii) the “parity value” of the “default amount” paid in shares as defined in the terms of the agreements. On October 15, 2013 the notes payable principal and interest were settled in full by payment of $70,805, and a Stipulation of Discontinuance was filed with the court with respect the above referenced action.
	The Company’s subsidiary CelLynx Group, Inc. has received a Cease Trading Order from the British Columbia Securities Commission (BCSC) in 2012 alleging that the Company is in violation of the British Colombia reporting requirements. The BCSC has assumed that since two the Company's Directors are domiciled in BC that the company is controlled out of BC and therefore subject to its reporting requirements. The Company denies that premise and is appealing the issuance of the CTO.  No directors of the Company are currently resident in British Columbia.
	In addition to the above, the Company may become involved in legal proceedings in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Subsequent Events	'
	Note 16 Subsequent events
	Sales of Common Stock
	During the period January 31, 2014 to March 6, 2014 the Company issued 6,375,000 units at a price of $0.10 per unit for aggregate proceeds of $637,500. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.30 per share acquired, with a two year term on the attached warrant.
	During the period March 7, 2014 to March 14, 2014 the Company issued 3,733,333 units at a price of $0.15 per unit for aggregate proceeds of $560,000. Each unit is comprised of one share and one share purchase warrant to acquire a second share at a price of $0.30 per share acquired, with a two year term on the attached warrant.
	On January 15, 2014 the Company issued 100,000 shares at a price of $0.167 per share for the settlement of notes payable with a total value of $16,700.
	On February 10, 2014 the Company issued 405,581 shares at a price of $0.2465 per share for services with a total value of $100,000.
	On February 10, 2014 the Company issued 1,250,000 shares at a price of $0.23 per share for services with a total value of $287,500.
	Issuance of Employee and Director Stock Options
	On January 13, 2014 the Board of Directors of the Company granted options to acquire 8,150,000 common shares, to certain Directors, employees and consultants of the Company, pursuant to the Stock Incentive Plan established by the Company on May 17, 2013. The options have an exercise price of $0.17 per share and are subject to variable vesting periods ranging from immediate vesting to vesting over the period ended January 13, 2015.
	Delivery of Initial Commercial Order
	In early 2014 the Company delivered its first commercial order, comprised of 1,000 Road Warrior, cellular network extenders to a purchaser in Mexico City, Mexico.

Summary_of_significant_account1

Summary of significant accounting policies (Policies)

12 Months Ended

Dec. 31, 2013

Accounting Policies [Abstract]

'

Basis of Presentation

'

Basis of presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The accompanying consolidated financial statements include the accounts of 5BARz International Inc., and its 94.3% owned subsidiary, 5BARz AG, and it’s 60% owned subsidiary CelLynx Group, Inc. and that Company’s 100% owned subsidiary CelLynx, Inc. All intercompany accounts and transactions have been eliminated upon consolidation.

Cash

'

Cash

Cash and cash equivalents include cash in hand and cash in time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of one year or less.

Use of estimates

'

Use of estimates

The preparation of these financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include impairment analysis for long lived assets, income taxes, litigation and valuation of derivative instruments. Actual results could differ from those estimates.

Concentration of credit risk

'

Concentration of credit risk

Cash includes deposits in accounts maintained at financial institutions.  Certain financial instruments, which subject the Company to concentration of credit risk, consist of cash. The Company maintains balances at financial institutions which, from time to time, may exceed Federal Deposit Insurance Corporation insured limits for the banks located in the United States. As of December 31, 2013 and 2012, the Company did not have any deposits in excess of federally-insured limits.  To date, the Company has not experienced any losses in such accounts.

Research and development costs

'

Research and Development Costs

Research and Development costs are charged to expense as incurred. The costs of materials and equipment that are required or constructed for research and development activities, and have alternative future uses (either in research and development, marketing or production), are classified as property and equipment and depreciated over their estimated useful lives.

Equipment

'

Furniture & equipment

Furniture & equipment is recorded at historical cost and is depreciated using the straight-line method over their estimated useful lives.  The useful life and depreciation method are reviewed periodically to ensure that the depreciation method and period are consistent with the anticipated pattern of future economic benefits. Expenditures for maintenance and repairs are charged to operations as incurred while renewals and betterments are capitalized. Gains and losses on disposals are included in the results of operations. The useful life of the equipment is being depreciated over three to seven years.

Inventory

'

Inventory

Inventories are carried at the lower of cost and net realizable value. Cost is determined using the weighted-average method.   As of December 31, 2013 the Company’s inventory included 1,000 units of Road Warrior cellular networks extenders.

Goodwill and other intangible assets

'

Goodwill and other intangible assets

The Company accounts for goodwill and intangible assets in accordance with the accounting guidance which requires that goodwill and other intangibles with indefinite lives be tested for impairment annually or on an interim basis if events or circumstances indicate that the fair value of an asset has decreased below its carrying value. The Accounting Standards Codification (“Codification”) requires that goodwill be tested for impairment at the reporting unit level (operating segment or one level below an operating segment). Application of the goodwill impairment test requires judgment, including the identification of reporting units, assigning assets and liabilities to reporting units, assigning goodwill to reporting units, and determining the fair value. Significant judgment is required to estimate the fair value of reporting units which includes estimating future cash flows, determining appropriate discount rates and other assumptions. Changes in these estimates and assumptions could materially affect the determination of fair value and/or goodwill impairment.

When testing goodwill for impairment, the Company may assess qualitative factors for some or all of its reporting units to determine whether it is more likely than not (that is, a likelihood of more than 50 percent) that the fair value of a reporting unit is less than its carrying amount, including goodwill. Alternatively, the Company may bypass this qualitative assessment for some or all of our reporting units and perform a detailed quantitative test of impairment (step 1). If the Company performs the detailed quantitative impairment test and the carrying amount of the reporting unit exceeds its fair value, the Company would perform an analysis (step 2) to measure such impairment. In 2013, the Company first performed a qualitative assessment to identify and evaluate events and circumstances to conclude whether it is more likely than not that the fair value of the Company’s reporting unit is less than its carrying amount. Based on the Company’s qualitative assessments, the Company concluded that a positive assertion can be made from the qualitative assessment that it is not more likely than not that the fair value of the reporting unit is less than its carrying amount. In accordance with the Codification, the Company reviews the carrying value of its intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparing the carrying amount of the asset or asset group to the undiscounted cash flows that the asset or asset group is expected to generate. If the undiscounted cash flows of such assets are less than the carrying amount, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group, if any, exceeds its fair market value. No impairment was deemed to exist as of December 31, 2013 and 2012.

Long-Lived Assets Subject to Amortization

'

Long-Lived Assets Subject to Amortization

The Company amortizes intangible assets with finite lives over their estimated useful lives and reviews them for impairment annually or whenever an impairment exists. The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment would be based on generally accepted valuation methodologies, as deemed appropriate. There were no long-lived assets impairment charges recorded during the years ended December 31, 2013 and 2012.

Revenue recognition

'

Revenue recognition

The Company's revenue recognition policies are in compliance with ASC Topic 605, “Revenue Recognition.”  Revenue is recognized at the date of shipment to customers, and when the price is fixed or determinable, the delivery is completed, no other significant obligations of the Company exist and collectability is reasonably assured.

Foreign currency translation

'

Foreign currency translation

Transactions in foreign currencies have been translated into US dollars using the temporal method. The functional currency of the Company’s subsidiary 5BARz AG, is its local currency (Swiss Franc – CHF). Under this method, monetary assets and liabilities are translated at the year-end exchange rate. Non-monetary assets have been translated at the historical rate of exchange prevailing at the date of the transaction. Expenses have been translated at the exchange rate at the time of the transaction. Realized and unrealized foreign exchange gains and losses are included in operations.

Fair value of financial instruments

'

Fair value of financial instruments

The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities, approximate fair value due to the short-term nature of these instruments.

Fair value is defined as an exit price, representing the amount that would be received upon the sale of an asset or payment to transfer a liability in an orderly transaction between market participants. Fair value is a market-based measurement that is determined based on assumptions that market participants would use in pricing an asset or liability. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows:

•

Level 1. Quoted prices in active markets for identical assets or liabilities.

•

Level 2. Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly.

•

Level 3. Significant unobservable inputs that cannot be corroborated by market data.

The assets or liability’s fair value measurement within the fair value hierarchy is based upon the lowest level of any input that is significant to the fair value measurement. The following table provides a summary of the assets that are measured at fair value on a recurring basis.

Consolidated

Quoted Prices in Active Markets for Identical Assets or Liabilities

Quoted Prices for Similar Assets or Liabilities in Active Markets

Significant

Balance Sheet

(Level 1)

(Level 2)

Unobservable

Inputs

(Level 3)

Derivative Liabilities:

31-Dec-13

$

60,018

$

—

$

—

$

60,018

31-Dec-12

$

—

$

—

$

—

$

—

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial liabilities that are measured at fair value on a recurring basis:

31-Dec-13

31-Dec-12

Beginning balance

$

—

$

—

Aggregate fair value of conversion feature upon issuance

57,995

469,332

Change in fair value of derivative liabilities

2,023

(469,332

)

Ending balance

$

60,018

$

—

The derivative conversion feature liabilities are measured at fair value using the Black-Scholes pricing model and are classified within Level 3 of the valuation hierarchy. The significant assumptions and valuation methods that the Company used to determine fair value and the change in fair value of the Company’s derivative financial instruments are provided below:

31-Dec-13

31-Dec-12

Stock price

$

0.25

$

0.05

Volatility

211

%

240

%

Risk-free interest rate

0.04

%

0.04

%

Dividend yield

0

%

0

%

Expected life

0.002 years

0.02 years

Level 3 liabilities are valued using unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the derivate liabilities. For fair value measurements categorized within Level 3 of the fair value hierarchy, the Company’s accounting and finance department, which reports to the Chief Financial Officer, determines its valuation policies and procedures. The development and determination of the unobservable inputs for Level 3 fair value measurements and fair value calculations are the responsibility of the Company’s accounting and finance department with support from the Company’s consultants and which are approved by the Chief Financial Officer.

Level 3 financial liabilities consist of the derivative liabilities for which there is no current market such that the determination of fair value requires significant judgment or estimation. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate.

The Company uses the Black-Scholes option valuation model to value Level 3 financial liabilities at inception and on subsequent valuation dates. This model incorporates transaction details such as the Company’s stock price, contractual terms, maturity, risk free rates, as well as, volatility.

As of December 31, 2013 there were no transfers in or out of Level 3 from other levels in the fair value hierarchy.

Derivative Instruments

'

Derivative Instruments

The Company evaluates its convertible instruments, options, warrants or other contracts to determine if those contracts or components of those contracts qualify as derivatives to be separately accounted for under ASC Topic 815, “Derivatives and Hedging”. The result of this accounting treatment is that the fair value of the derivative is marked-to-market each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income (expense). Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Equity instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815 are reclassified to liability at the fair value of the instrument on the reclassification date.

Stock-based Compensation

'

Stock-Based Compensation

The Company records stock-based compensation in accordance with ASC Topic 718, “Compensation – Stock Compensation.” ASC 718 requires companies to measure compensation cost for stock-based employee compensation at fair value at the grant date and recognize the expense over the employee’s requisite service period. Under ASC 718, the Company’s volatility is based on the historical volatility of the Company’s stock or the expected volatility of similar companies. The expected life assumption is primarily based on historical exercise patterns and employee post-vesting termination behavior. The risk-free interest rate for the expected term of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

The Company uses the Black-Scholes option-pricing model which was developed for use in estimating the fair value of options. Option-pricing models require the input of highly complex and subjective variables including the expected life of options granted and the Company’s expected stock price volatility over a period equal to or greater than the expected life of the options. Because changes in the subjective assumptions can materially affect the estimated value of the Company’s employee stock options, it is management’s opinion that the Black-Scholes option-pricing model may not provide an accurate measure of the fair value of the Company’s employee stock options. Although the fair value of employee stock options is determined in accordance with ASC 718 using an option-pricing model, that value may not be indicative of the fair value observed in a willing buyer/seller market transaction.

The Company recognizes in the statement of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and non-employees.

Income Taxes

'

Income taxes

The Company accounts for income taxes in accordance with ASC Topic 740, “Income Taxes.” ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized.  Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company is open for examination for the years 2009, 2010, 2011, 2012 and 2013. Penalties and interest incurred related to underpayment of income tax are classified as income tax expense in the period incurred.  No significant penalties or interest relating to income taxes have been incurred during the years ended December 31, 2013 and 2012.

Net loss per share

'

Net loss per share

The Company reports loss per share in accordance with the ASC Topic 260, “Earnings Per Share.”, which requires presentation of basic and diluted EPS on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation.  In the accompanying financial statements, basic earnings per share of common stock is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period plus the issuance of common shares, if dilutive, that could result from the exercise of outstanding stock options and warrants. These potentially dilutive securities of 49,855,171 and 8,540,000, respectively were not included in the calculation of loss per common share for the years ended December 31, 2013 or 2012 because their effect would be anti-dilutive. The weighted average number of shares outstanding does not include reciprocal shareholdings, held by the Company’s subsidiary, CelLynx Group, Inc. which is reflected as a reduction in capital in excess of par value on the Company’s balance sheet.

Recent accounting pronouncements

'

Recent Accounting Pronouncements

In July 2012, the FASB issued ASU 2012-02, “Intangibles-Goodwill and Other (Topic 350): Testing Indefinite-Lived Intangible Assets for Impairment."  This ASU simplifies how entities test indefinite-lived intangible assets for impairment which improve consistency in impairment testing requirements among long-lived asset categories. These amended standards permit an assessment of qualitative factors to determine whether it is more likely than not that the fair value of an indefinite-lived intangible asset is less than its carrying value. For assets in which this assessment concludes it is more likely than not that the fair value is more than its carrying value, these amended standards eliminate the requirement to perform quantitative impairment testing as outlined in the previously issued standards. The guidance is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012, early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s consolidated financial position and results of operations.

In February 2013, the FASB issued ASU No. 2013-02, Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (“ASU 2013-02”).  The amendment requires disclosure of information about the amounts reclassified out of accumulated other comprehensive income by component. In addition, disclosure is required, either on the face of the statement where net income is presented or in the notes, of significant amounts reclassified out of accumulated other comprehensive income by the respective line items of net income but only if the amount reclassified is required under U.S. GAAP to be reclassified to net income in its entirety in the same reporting period. For other amounts that are not required under U.S. GAAP to be reclassified in their entirety to net income, an entity is required to cross-reference to other disclosures required under U.S. GAAP that provide additional detail about those amounts. The new requirements are effective for public companies in interim and annual reporting periods beginning after December 15, 2012. The adoption of ASU 2013-02 as of January 1, 2013 did not have an impact on the Company's consolidated financial statements.

The FASB has issued ASU No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force). The amendments in this ASU state that an unrecognized tax benefit, or a portion of an unrecognized tax benefit, should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward, except as follows. To the extent a net operating loss carryforward, a similar tax loss, or a tax credit carry-forward is not available at the reporting date under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position or the tax law of the applicable jurisdiction does not require the entity to use, and the entity does not intend to use, the deferred tax asset for such purpose, the unrecognized tax benefit should be presented in the financial statements as a liability and should not be combined with deferred tax assets. The amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. For nonpublic entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2014. Early adoption is permitted. The amendments should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Retrospective application is permitted. The Company has not yet determined the effect of the adoption of this standard and it is expected to have a material impact on the Company’s consolidated financial position and results of operations.

FASB, the Emerging Issues Task Force and the SEC have issued certain other accounting standards, updates, and regulations as of December 31, 2013 that will become effective in subsequent periods; however, management does not believe that any of those updates would have significantly affected our financial accounting measures or disclosures had they been in effect during 2013 or 2012, and it does not believe that any of those pronouncements will have a significant impact on our consolidated financial statements at the time they become effective.

Summary_of_Accounting_Policies

Summary of Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2013
Summary Of Accounting Policies Tables	'
Fair Value of Financial instruments Assets and Liabilities	'
		Consolidated			Quoted Prices in Active Markets for Identical Assets or Liabilities			Quoted Prices for Similar Assets or Liabilities in Active Markets		Significant
		Balance Sheet			(Level 1)			(Level 2)		Unobservable
										Inputs
										(Level 3)
	Derivative Liabilities:
	31-Dec-13	$	60,018		$	—		$	—	$	60,018
	31-Dec-12	$	—		$	—		$	—	$	—
Level 3 financial liabilities that are measured at fair value on a recurring basis	'
		31-Dec-13			31-Dec-12
	Beginning balance	$	—		$	—
	Aggregate fair value of conversion feature upon issuance		57,995			469,332
	Change in fair value of derivative liabilities		2,023			(469,332	)
	Ending balance	$	60,018		$	—
Fair Value of Financial instruments Black-Scholes option pricing models	'
		31-Dec-13			31-Dec-12
	Stock price	$	0.25		$	0.05
	Volatility		211	%		240	%
	Risk-free interest rate		0.04	%		0.04	%
	Dividend yield		0	%		0	%
	Expected life		0.002 years			0.02 years

Furniture_Equipment_Tables

Furniture & Equipment (Tables)	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Furniture & Equipment	'
		31-Dec-13			31-Dec-12
	Office furniture and equipment	$	70,804		$	14,532
	Research and development equipment (i)		169,350			-
	Leasehold improvements		6,940			-
			247,094			14,532
	Accumulated amortization & depreciation		(21,111	)		-10,126
	Furniture & equipment net	$	225,983		$	4,406

Long_lived_assets_and_goodwill1

Long lived assets and goodwill subject to amortization (Tables)	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Intangible Assets	'
				31-Dec-13			31-Dec-12
	Technology		$	3,015,794		$	3,015,794
	Marketing and distribution agreement			370,000			370,000
	Trademarks			264			264
	License rights			1,348			1,348
				3,387,406			3,387,406
	Accumulated amortization			-			-
	Technology and other intangibles, net		$	3,387,406		$	3,387,406
Estimated amortization of intangible assets	'
	For the years ended
	December 31,						Marketing and		Trademark & license
			Total		Technology		distribution agreement		agreements
	2014	$	251,722	$	177,400	$	74,000	$	322
	2015		251,722		177,400		74,000		322
	2016		251,722		177,400		74,000		322
	2017		251,722		177,400		74,000		322
	2018		251,724		177,400		74,000		324
	Future years		2,128,794		2,128,794		-		-
		$	3,387,406	$	3,015,794	$	370,000	$	1,612

Goodwill_Tables

Goodwill (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill	'
			31-Dec-13		31-Dec-12
	Goodwill – beginning of year	$	1,140,246	$	-
	Acquisition of CelLynx Group, Inc.		-		556,913
	Fair value of non-controlling interest		-		583,333
	Goodwill – end of year	$	1,140,246	$	1,140,246

Income_taxes_Tables

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Investments [Abstract]	'
Domestic and Foreign components of income (loss) before income taxes	'
		31-Dec-13			31-Dec-12
	Domestic	$	(2,251,545	)	$	(1,882,912	)
	Foreign		(45,055	)		(144,481	)
	Loss from continuing operation before	$	(2,296,600	)	$	(2,027,393	)
	provision for income taxes
Income tax provision (benefit)	'
		31-Dec-13			31-Dec-12
	Foreign
	Current	$	0		$	0
	Deferred		(9,912	)		(46,159	)
	US federal
	Current		0			0
	Deferred		(604,970	)		(980.972	)
	State & local
	Current		0			0
	Deferred		(214,066	)		(84,897	)
	Total		(828,948	)		(1,112,028	)
	Change in valuation allowance		828,948			1,112,028
	Income tax provision (benefit)	$	0		$	0
Reconciliation of statutory and effective income tax rate	'
		31-Dec-13			31-Dec-12
	US federal statutory income tax rate (benefit)		(34.0	%)		(34.0	%)
	State income taxes		(5.8	%)		(2.3	%)
	Fair value of beneficial conversion feature		1	%		(7.5	%)
	Acquired deferred balances		0	%		(11.2	%)
	Stock based compensation		10.4	%		0	%
	Other permanent differences		0.5	%		0.1	%
	Change in valuation allowance		27.9	%		54.9	%
	Effective rate		0	%		0	%
Deferred Tax asset and liability	'
		31-Dec-13			31-Dec-12
	Deferred tax assets
	Net operating loss carryovers	$	2,077,660		$	1,261,422
	R&D credit		66,017			0
	Accrued compensation		202,375			167,355
	Stock-based compensation		2,833			2,833
	Total deferred tax assets		2,348,886			1,431,610
	Valuation allowance		(2,163,259	)		(1,334,310	)
	Deferred tax asset, net of valuation allowance		185,627			97,300
	Deferred tax liabilities
	Fixed asset depreciation		(14,024	)		(170	)
	Intangible asset amortization		(171,602	)		(97,130	)
	Total deferred tax liabilities		(185,627	)		(97,300	)
	Net deferred tax asset (liability)	$	0		$	0

Convertible_Securities_Tables

Convertible Securities (Tables)	12 Months Ended
	Dec. 31, 2013
Convertible Securities Tables	'
Convertible Promissory Note	'
		Unpaid		Note	Unpaid		Balance		Balance
		Note Principal		Terms	Interest & penalty		31-Dec-13		31-Dec-12
	Issue Date
	5BARz International, Inc.
	27-Feb-12	$	-	(a)	$	-	$	-	$	40,832
	3-May-12		-	(b)		-		-		67,131
	18-Sep-12		-	(c)		-		-		20,712
	3-Feb-12		-	(d)				-		207,500
	8-Jun-12		50,000	(d)		53,997		103,997		100,000
	17-Dec-12		80,000	(e)		6,645		86,645		—
	8-Jan-13		147,428	(f)		6,589		154,017		—
	Notes payable – 5BARz International Inc.	$	277,428		$	67,231	$	344,659	$	436,175
	CelLynx Group Inc.
	November. 10, 2007	$	-	(g)	$	-	$	-	$	316,693
	5-Apr-11		-	(h)		-		-		98,613
	5-Jan-12		-	(i)		-		-		80,438
	24-May-12		19,500	(j)		18,322		37,822		42,433
	12-Sep-12		12,500	(k)		15,202		27,702		19,202
	Notes payable CelLynx Group, Inc.	$	32,000		$	33,524	$	65,524	$	557,379
	Total	$	309,428		$	100,755	$	410,183	$	993,554

Captial_Lease_Obligation_Table

Captial Lease Obligation (Tables)	12 Months Ended
	Dec. 31, 2013
Captial Lease Obligation Tables	'
Minimum Lease Payments	'
	2014	$	60,000
	2015	$	60,000
	2016	$	50,000
	Total	$	170,000
	Interest (12%)	$	9,536
	Capitalized valuation of equipment	$	160,464

Options_and_Warrants_Tables

Options and Warrants (Tables)	12 Months Ended
	Dec. 31, 2013
Options And Warrants Tables	'
Warrants - 5BARz International Inc.	'
		Number of		Weighted Average		Average Remaining
		Warrants		Exercise Price		Contractual Life
	Outstanding at December 31, 2012		2,140,000	$	0.2		2
	Granted		47,040,103	$	0.26
	Exercised		—		—
	Cancelled		1,600,000	$	0.2
	Outstanding at December 31, 2013		47,580,103	$	0.26		1.64
	Exercisable at December 31, 2013		47,580,103	$	0.26		1.64
Options- 5BARz International Inc.	'
		Number of Options		Weighted Average Exercise Price		Weighted Average
						Remaining Contractual
						Life (years)
	Outstanding – December 31, 2012		—		—
	Granted		4,000,000		0.1		2.5
	Outstanding – December 31, 2013		4,000,000		0.1		2.5
	Exercisable- December 31, 2013		1,079,452		0.1		2.5
Options-CelLynx Group, Inc.	'
		Number of Options		Weighted Average Exercise Price		Weighted Average
						Remaining Contractual
						Life (years)
	Outstanding – December 31, 2012		6,400,000		0.0008		2.5
	Cancelled		6,400,000		0.0008		2.5
	Granted		65,000,000		0.0002		4.6
	Outstanding – December 31, 2013		65,000,000		0.0002		4.6
	Exercisable- December 31, 2013		65,000,000		0.0002		4.6
Warrants - CelLynx Group, Inc.	'
		Number of		Weighted Average		Average Remaining
		Warrants		Exercise Price		Contractual Life
	Outstanding at December 31, 2012		5,930,000	$	0.12
	Granted
	Exercised		—		—
	Expired		1,430,000		0.12
	Outstanding at December 31, 2013		4,500,000	$	0.96		1.15
	Exercisable at December 31, 2013		4,500,000	$	0.96		1.15

Investment_in_CelLynx_Group_In1

Investment in CelLynx Group, Inc. (Tables)	12 Months Ended
	Dec. 31, 2013
Notes to Financial Statements	'
Acquistion of Cellynx Group, Inc.	'
	i.	Cash consideration paid		$	170,000
	ii.	1,250,000 common shares of the registrant issued at a market price of $0.20 per share			250,000
	iii.	Redemption of convertible debt for 350 million shares of CelLynx Group Inc. common stock			455,000	(a)
		Fair market value of consideration paid		$	875,000
Assets and Liabilities recognized at acquisition date	'
	Description	Net book value of CelLynx Group, Inc. consolidated assets and liabilities				Acquisition			Valuation attributed to assets acquired
						Adjustments (i) (ii)
	Current assets	$	3,260						$	3,260
	Patented and unpatented technology, trademarks, and license		44,718			$	1,155,282	(ii)		1,200,000
	Investment in 5BARz   (iii)		1,800,000							1,800,000
	Furniture and equipment		2,113							2,113
	Accounts payable and accruals		(1,752,628	)						(1,752,628	)
	Notes payable (net of discount)		(403,076	)						(403,076	)
	Accrued interest		(62,250	)						(62,250	)
	Derivative liability		(5,495,425	)			5,026,093	(i)		(469,332	)
	LOC payable – 5BARz (net)		(586,525	)			586,525	(i)		—
	Fair value non-controlling interest						(583,333	)		(583,333	)
	Totals	$	(6,449,813	)		$	6,184,567			(265,246	)
	Goodwill									1,140,246
	Purchase price								$	875,000
Pro Forma Combined Financial Information	'
		For the Year Ended December 31, 2012
	Revenues	$	0
	Net loss after non-controlling interest	$	(1,070,117	)
	Pro forma basic and diluted net loss per common share	$	(0.01	)
	Pro forma weighted average common shares outstanding – basic and diluted		97,833,528

Organization_and_Basis_of_Repo

Organization and Basis of Reporting (Details)	12 Months Ended	9 Months Ended
	Dec. 31, 2013	Sep. 30, 2012
	5BARz AG	CelLynx Group, Inc.
Business Acquisition [Line Items]	'	'
Agreement date	6-Nov-11	29-Mar-12
Acquired interest	94.30%	'
Ownership in Entity	'	'CeLlynx Inc.
Percentage Owned	60.00%	100.00%

Going_concern_Details

Going concern (Details) (USD $)	62 Months Ended
	Dec. 31, 2013
Going Concern Details	'
Net loss	$5,158,370
Negative Cash Flows	3,601,301
Accumulated Deficit	$5,173,598

Summary_of_Accounting_Policies1

Summary of Accounting Policies (Details) (Level 3, USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Level 3	'	'
Derivative Liabilities	'	'
Aggregate fair value of conversion feature upon issuance	57,995	469,332
Change in fair value of derivative liabilities	2,023	-469,332
Derivative Liabilities	$60,018	'
Level 3 Valuation Methodolgy	'	'
Stock Price	$0.25	$0.05
Expected volatility	211.00%	240.00%
Risk-free Interest	0.04%	0.04%
Annual Dividend Yield	0.00%	0.00%
Exepected Life (years)	'2 days	'2 months
Net loss per share	'	'
Dilutive securities	49,855,171	8,540,000

Equipment_Details_Narrative

Equipment (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	$247,094	$14,532
Accumulated depreciation	-21,111	10,126
Furniture & equipment net	225,983	4,406
Office furniture and equipemnt	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	70,804	14,532
Research and development equipment	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	169,350	'
Leasehold improvements	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and Equipment	$6,940	'

Equipment_Additional_Details_N

Equipment Additional (Details Narrative) (USD $)	12 Months Ended		62 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Equipment Additional Details Narrative	'	'	'
Depreciation Expense	$10,985	$1,451	$15,558

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Intangible Assets, Gross	$3,387,406	$3,387,406
Accumulated amortization	'	'
Intangibles Assets, net	3,387,406	3,387,406
Technology	'	'
Intangible Assets, Gross	3,015,794	3,015,794
Marketing and distribution agreement	'	'
Intangible Assets, Gross	370,000	370,000
Trademark and license agreement	'	'
Intangible Assets, Gross	264	264
License rights	'	'
Intangible Assets, Gross	$1,348	$1,348

Intangible_Assets_Details_Narr

Intangible Assets (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013
Estimated Amortization-2014	$251,722
Estimated Amortization-2015	251,722
Estimated Amortization-2016	251,722
Estimated Amortization-2017	251,722
Estimated Amortization-2018	251,722
Estimated Amortization- Future years	2,128,794
Total Estimated Amortization	3,387,406
Patented and unpatented technology	'
Life of amortization	'5 years
Total Estimated Amortization	887,000
Technology	'
Estimated Amortization-2014	177,400
Estimated Amortization-2015	177,400
Estimated Amortization-2016	177,400
Estimated Amortization-2017	177,400
Estimated Amortization-2018	177,400
Estimated Amortization- Future years	2,128,794
Total Estimated Amortization	3,015,794
Marketing and distribution agreement	'
Estimated Amortization-2014	74,000
Estimated Amortization-2015	74,000
Estimated Amortization-2016	74,000
Estimated Amortization-2017	74,000
Estimated Amortization-2018	74,000
Total Estimated Amortization	370,000
Trademark and license agreement	'
Estimated Amortization-2014	161
Estimated Amortization-2015	161
Estimated Amortization-2016	161
Estimated Amortization-2017	161
Estimated Amortization-2018	162
Total Estimated Amortization	$1,612
Maximum	'
Life of amortization	'20 years
Minimum	'
Life of amortization	'10 years

Goodwill_Goodwill_Details

Goodwill - Goodwill (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Goodwill- beginning of year	$1,140,246	$1,140,246
Acquisition of Cellynx Group, Inc.	'	556,913
Fair value of non-controlling interest	'	583,333
Goodwill-end of year	$1,140,246	$1,140,246

Domestic_and_Foreign_Component

Domestic and Foreign Components of income (loss) (Details) (USD $)	12 Months Ended		62 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Domestic And Foreign Components Of Income Loss Details	'	'	'
Domestic	($2,251,545)	($1,882,912)	'
Foreign	-45,055	-144,481	'
Net (loss) before non-controlling interest	($2,296,600)	($2,027,393)	($5,158,370)

Income_Tax_Provision_benefit_D

Income Tax Provision (benefit) (Details) (USD $) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Foreign	'	'
Current	$0	$0
Deferred	-9,912	-46,159
US federal	'	'
Current	0	0
Deferred	-604,970	-980
State & local	'	'
Current	0	0
Deferred	-214,066	-84,897
Total	-828,948	-1,112,028
Change in valuation allowance	828,948	1,112,028
Income tax provision (benefit)	$0	$0

Reconciliation_of_statutory_an

Reconciliation of statutory and effective income tax rate (Details)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Schedule of Investments [Abstract]	'	'
US federal statutory income tax rate (benefit)	-34.00%	-34.00%
State income taxes	-5.80%	-2.30%
Fair value of beneficial conversion feature	1.00%	-0.75%
Acquired deferred balances	0.00%	-1120.00%
Stock based compensation	-10.40%	0.00%
Other permanent differences	-0.50%	-0.10%
Change in valuation allowance	27.90%	54.90%
Effective rate	0.00%	0.00%

Deferred_Tax_asset_and_liabili

Deferred Tax asset and liability (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carry-forwards	$2,077,660	$1,261,422
R&D credit	66,017	0
Accrued compensation	202,375	167,355
Stock-based compensation	2,833	2,833
Total deferred tax assets	2,348,886	1,431,610
Valuation allowance	-2,163,259	-1,334,310
Deferred tax asset, net of valuation allowance	185,627	97,300
Deferred tax liabilities	'	'
Fixed asset depreciation	-14,024	-170
Intangible asset amortization	-171,602	-97,130
Total deferred tax liabilities	-185,627	-97,300
Net deferred tax assets (liability)	$0	$0

Federal_income_tax_Details_Nar

Federal income tax (Details Narrative) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Schedule of Investments [Abstract]	'	'
US Federal net operating loss	$5,075,000	$3,375,000
State net operating loss	2,950,000	1,159,000
Cellynx net operating loss annual limitation	8,700	'
Cellynx net operating loss	8,600,000	'
Change in valuation allowance	$828,949	$1,334,310

Cumulative_Sales_of_Stock_2008

Cumulative Sales of Stock 2008-2010 (Details)	Nov. 13, 2008	Dec. 31, 2010	Dec. 31, 2012	Dec. 31, 2010	Dec. 31, 2008	Nov. 30, 2010
	Founders Shares	Common Stock	Common Stock	Common Stock	Common Stock	Stock Split
Issuance of restricted common stock/founders shares	7,100,000	'	'	'	1,776,100	'
Forward stock split	'	'	'	'	'	18
Authorized Shares-before stock split	'	'	'	'	'	100,000,000
Authorized Shares-After Stock split	'	'	'	150,893,700	'	250,000,000
Cancellation of Common Stock, shares	'	87,800,000	'	'	'	'
Common stock issued forAcquistions (in shares)	'	15,600,000	1,250,000	'	'	'

Cumulative_Sales_of_Stock_2011

Cumulative Sales of Stock 2011 (Details) (USD $)

1 Months Ended

12 Months Ended

3 Months Ended

0 Months Ended

1 Months Ended

Dec. 31, 2008

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2011

Dec. 19, 2011

Dec. 15, 2011

Dec. 07, 2011

Nov. 08, 2011

Oct. 20, 2011

Jul. 24, 2011

Jul. 21, 2011

Jul. 18, 2011

Jun. 03, 2011

Apr. 07, 2011

Apr. 04, 2011

Mar. 09, 2011

Jan. 15, 2011

Jan. 10, 2011

Dec. 31, 2011

Dec. 31, 2013

Conversion Of Convertible Debenture

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

5BARz

5BARz

Issuance of common stock (in shares)

'

'

'

'

'

'

150,000

455,180

75,000

200,000

37,500

40,000

69,610

25,000

5,000

200,000

350,000

150,000

200,000

300,000

21,000

'

Issuance of common stock

$17,745

$2,930,750

$520,000

$1,360,440

$13,650

'

$15,000

$45,581

$7,500

$30,000

$7,500

$20,000

$14,000

$25,000

$3,000

$200,000

$350,000

$150,000

$200,000

$300,000

$75,840

'

Conversion of Convertible Debenture Agreement (in shares)

'

'

'

'

'

335,695

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of Convertible Debenture Agreement (Euro's)

'

'

'

'

'

$67,513

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Price Per Unit

'

'

'

'

'

'

$0.10

$0.10

$0.10

$0.15

$0.20

$0.50

$0.20

$1

$0.70

$1

$1

$1

$1

$1

'

$3.26

Cumulative_Sales_of_Stock_2012

Cumulative Sales of Stock 2012 (Details) (USD $)

0 Months Ended

1 Months Ended

4 Months Ended

12 Months Ended

Mar. 06, 2014

Dec. 31, 2013

Nov. 15, 2013

Jul. 03, 2013

Jun. 30, 2013

28-May-13

23-May-13

15-May-13

Apr. 10, 2013

Apr. 02, 2013

Mar. 31, 2013

Mar. 17, 2013

Mar. 01, 2013

Feb. 26, 2013

Feb. 15, 2013

Feb. 12, 2013

Jan. 25, 2013

Dec. 31, 2012

Dec. 17, 2012

Dec. 12, 2012

Dec. 07, 2012

Oct. 26, 2012

Oct. 12, 2012

Sep. 14, 2012

Sep. 10, 2012

Sep. 05, 2012

Aug. 14, 2012

Aug. 10, 2012

Jul. 20, 2012

Jul. 09, 2012

Jun. 27, 2012

Jun. 21, 2012

Jun. 12, 2012

14-May-12

3-May-12

Apr. 30, 2012

Apr. 18, 2012

Apr. 02, 2012

Mar. 26, 2012

Mar. 22, 2012

Mar. 20, 2012

Mar. 07, 2012

Mar. 05, 2012

Feb. 29, 2012

Feb. 07, 2012

Feb. 01, 2012

Jan. 12, 2012

Dec. 31, 2008

Nov. 18, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Issuance of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$17,745

'

$2,930,750

$520,000

$1,360,440

$13,650

Common stock issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

228,740

798,463

7,500

'

Stock Issued During Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

772,441

'

'

'

Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock (in shares)

29,215,000

[1]

740,000

[1]

'

'

'

100,000

'

200,000

600,000

'

'

'

600,000

'

'

'

'

'

'

'

'

100,000

'

'

401,338

'

500,000

500,000

250,000

200,000

50,000

'

95,000

20,000

80,000

'

100,000

'

50,000

170,000

333,334

150,000

433,334

200,000

500,000

'

'

'

'

'

'

'

'

Units Issued (in shares)

'

'

'

'

'

'

200,000

'

'

425,000

'

'

'

'

'

'

'

400,000

1,200,000

400,000

'

'

300,000

300,000

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

Issuance of common stock

2,921,500

'

'

'

586,750

50,000

10,000

10,000

30,000

21,250

'

'

30,000

'

'

'

'

20,000

60,000

20,000

'

5,000

15,000

15,000

12,000

5,000

25,000

25,000

52,000

52,000

5,000

'

9,500

2,000

8,000

'

15,000

'

6,000

25,500

50,000

18,000

52,000

20,000

50,000

'

'

1,776

'

35,775

6,542

2,182

15,600

Common stock issued for services (in shares)

'

14,350,000

[1]

'

331,200

[1]

'

'

'

'

'

'

100,000

513,827

175,000

'

14,400,000

'

100,000

2,250,000

'

'

3,300,824

'

'

'

'

'

'

'

'

'

'

2,150,000

'

'

'

125,000

'

250,000

'

'

'

'

'

100,000

'

1,500,000

300,000

'

'

'

'

'

'

Common stock issued for services

'

71,750

'

66,240

'

'

'

'

'

'

5,000

25,691

8,750

'

72,000

'

5,000

112,500

'

'

165,041

'

'

'

'

'

'

'

'

'

'

212,620

'

'

'

14,977

'

30,000

'

'

'

'

'

47,990

'

150,000

30,000

'

'

3,581

10,042

75

'

Shares issued for Debt, shares

'

'

25,000

'

'

'

'

'

'

'

'

'

'

250,000

'

125,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,689,710

'

'

'

Stock Issued During Period

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

7,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,690

'

'

'

Price Per Unit

$0.10

$0.20

$0.20

$0.20

'

$0.05

'

$0.05

$0.05

'

$0.05

$0.05

$0.05

$0.04

$0.05

$0.06

'

$0.05

$0.05

$0.05

$0.05

$0.05

$0.05

$0.05

$0.03

$0.20

$0.05

$0.05

$0.20

$0.10

$0.10

$0.10

$0.10

$0.10

$0.10

$0.12

$0.15

$0.12

$0.12

$0.15

$0.15

$0.12

$0.12

$0.48

$0.10

$0.10

$0.10

'

$0.10

$0.20

$0.05

'

'

Warrant price

0.3

0.3

'

'

'

'

0.2

'

'

0.2

0.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.3

0.3

'

'

'

Cash received for issuance of stock

637,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,044,103

'

'

'

'

Settlement of debt for common stock

'

74,000

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

604,411

'

'

'

'

Common Stock Additional

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Units Issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

140,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

91,780

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66,667

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

Common stock issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,589

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10,000

'

'

'

'

'

'

'

'

'

$5,000

'

'

'

'

'

'

'

Price Per Unit

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.05

'

'

'

'

'

'

'

'

'

'

'

'

$0.05

'

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

$0.10

'

'

'

'

'

'

'

[1]

Each unit is comprised of one share and one warrant to acquire a second share, with a two year warrant term.

Cumulative_Sales_of_Stock_2013

Cumulative Sales of Stock 2013 (Details) (USD $)

0 Months Ended

1 Months Ended

4 Months Ended

12 Months Ended

Mar. 06, 2014

Dec. 31, 2013

Nov. 15, 2013

Jul. 03, 2013

Jun. 30, 2013

28-May-13

23-May-13

15-May-13

Apr. 10, 2013

Apr. 02, 2013

Mar. 31, 2013

Mar. 17, 2013

Mar. 01, 2013

Feb. 26, 2013

Feb. 15, 2013

Feb. 12, 2013

Jan. 25, 2013

Dec. 31, 2012

Dec. 17, 2012

Dec. 12, 2012

Dec. 07, 2012

Oct. 26, 2012

Oct. 12, 2012

Sep. 14, 2012

Sep. 10, 2012

Sep. 05, 2012

Aug. 14, 2012

Aug. 10, 2012

Jul. 20, 2012

Jul. 09, 2012

Jun. 27, 2012

Jun. 21, 2012

Jun. 12, 2012

14-May-12

3-May-12

Apr. 30, 2012

Apr. 18, 2012

Apr. 02, 2012

Mar. 26, 2012

Mar. 22, 2012

Mar. 20, 2012

Mar. 07, 2012

Mar. 05, 2012

Feb. 29, 2012

Feb. 07, 2012

Feb. 01, 2012

Jan. 12, 2012

Dec. 31, 2008

Nov. 18, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2011

Dec. 31, 2010

Issuance of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$17,745

'

$2,930,750

$520,000

$1,360,440

$13,650

Common stock issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

228,740

798,463

7,500

'

Stock Issued During Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

772,441

'

'

'

Common Stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock (in shares)

29,215,000

[1]

740,000

[1]

'

'

'

100,000

'

200,000

600,000

'

'

'

600,000

'

'

'

'

'

'

'

'

100,000

'

'

401,338

'

500,000

500,000

250,000

200,000

50,000

'

95,000

20,000

80,000

'

100,000

'

50,000

170,000

333,334

150,000

433,334

200,000

500,000

'

'

'

'

'

'

'

'

Units Issued (in shares)

'

'

'

'

'

'

200,000

'

'

425,000

'

'

'

'

'

'

'

400,000

1,200,000

400,000

'

'

300,000

300,000

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

Issuance of common stock

2,921,500

'

'

'

586,750

50,000

10,000

10,000

30,000

21,250

'

'

30,000

'

'

'

'

20,000

60,000

20,000

'

5,000

15,000

15,000

12,000

5,000

25,000

25,000

52,000

52,000

5,000

'

9,500

2,000

8,000

'

15,000

'

6,000

25,500

50,000

18,000

52,000

20,000

50,000

'

'

1,776

'

35,775

6,542

2,182

15,600

Common stock issued for services (in shares)

'

14,350,000

[1]

'

331,200

[1]

'

'

'

'

'

'

100,000

513,827

175,000

'

14,400,000

'

100,000

2,250,000

'

'

3,300,824

'

'

'

'

'

'

'

'

'

'

2,150,000

'

'

'

125,000

'

250,000

'

'

'

'

'

100,000

'

1,500,000

300,000

'

'

'

'

'

'

Common stock issued for services

'

71,750

'

66,240

'

'

'

'

'

'

5,000

25,691

8,750

'

72,000

'

5,000

112,500

'

'

165,041

'

'

'

'

'

'

'

'

'

'

212,620

'

'

'

14,977

'

30,000

'

'

'

'

'

47,990

'

150,000

30,000

'

'

3,581

10,042

75

'

Common stock issued for debt, shares

'

'

25,000

'

'

'

'

'

'

'

'

'

'

250,000

'

125,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,689,710

'

'

'

Stock Issued During Period

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000

'

7,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

8,690

'

'

'

Price Per Unit

$0.10

$0.20

$0.20

$0.20

'

$0.05

'

$0.05

$0.05

'

$0.05

$0.05

$0.05

$0.04

$0.05

$0.06

'

$0.05

$0.05

$0.05

$0.05

$0.05

$0.05

$0.05

$0.03

$0.20

$0.05

$0.05

$0.20

$0.10

$0.10

$0.10

$0.10

$0.10

$0.10

$0.12

$0.15

$0.12

$0.12

$0.15

$0.15

$0.12

$0.12

$0.48

$0.10

$0.10

$0.10

'

$0.10

$0.20

$0.05

'

'

Warrant price

0.3

0.3

'

'

'

'

0.2

'

'

0.2

0.2

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.3

0.3

'

'

'

Cash received for issuance of stock

637,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

6,044,103

'

'

'

'

Settlement of debt for common stock

'

74,000

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

604,411

'

'

'

'

Common Stock Additional

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Units Issued (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

140,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued for services (in shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

91,780

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66,667

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

Common stock issued for services

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,589

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$10,000

'

'

'

'

'

'

'

'

'

$5,000

'

'

'

'

'

'

'

Price Per Unit

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.05

'

'

'

'

'

'

'

'

'

'

'

'

$0.05

'

'

'

'

'

'

'

'

$0.15

'

'

'

'

'

'

'

'

'

$0.10

'

'

'

'

'

'

'

[1]

Each unit is comprised of one share and one warrant to acquire a second share, with a two year warrant term.

Cumulative_Sales_of_Stock_Pric

Cumulative Sales of Stock Prices (Details) (USD $)

Mar. 06, 2014

Dec. 31, 2013

Nov. 18, 2013

Nov. 15, 2013

Jul. 03, 2013

28-May-13

15-May-13

Apr. 10, 2013

Mar. 31, 2013

Mar. 17, 2013

Mar. 01, 2013

Feb. 26, 2013

Feb. 15, 2013

Feb. 12, 2013

Dec. 31, 2012

Dec. 17, 2012

Dec. 12, 2012

Dec. 07, 2012

Oct. 26, 2012

Oct. 12, 2012

Sep. 14, 2012

Sep. 10, 2012

Sep. 05, 2012

Aug. 14, 2012

Aug. 10, 2012

Jul. 20, 2012

Jul. 09, 2012

Jun. 27, 2012

Jun. 21, 2012

Jun. 12, 2012

14-May-12

3-May-12

Apr. 30, 2012

Apr. 18, 2012

Apr. 02, 2012

Mar. 26, 2012

Mar. 22, 2012

Mar. 20, 2012

Mar. 07, 2012

Mar. 05, 2012

Feb. 29, 2012

Feb. 07, 2012

Feb. 01, 2012

Jan. 12, 2012

Dec. 31, 2013

Mar. 31, 2012

Mar. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Sep. 30, 2011

Jun. 30, 2011

Mar. 30, 2011

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2012

Mar. 31, 2012

Sep. 30, 2011

Jun. 30, 2011

Mar. 30, 2011

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Conversion Of Convertible Debenture

Common Stock for Services

Excess of Par Value

Minimum

Minimum

Minimum

Minimum

Minimum

Minimum

Minimum

Minimum

Minimum

Maximum

Maximum

Maximum

Maximum

Maximum

Maximum

Maximum

Maximum

Maximum

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Common Stock

Price Per Unit

$0.10

$0.20

$0.10

$0.20

$0.20

$0.05

$0.05

$0.05

$0.05

$0.05

$0.05

$0.04

$0.05

$0.06

$0.05

$0.05

$0.05

$0.05

$0.05

$0.05

$0.05

$0.03

$0.20

$0.05

$0.05

$0.20

$0.10

$0.10

$0.10

$0.10

$0.10

$0.10

$0.12

$0.15

$0.12

$0.12

$0.15

$0.15

$0.12

$0.12

$0.48

$0.10

$0.10

$0.10

$0.20

$0.10

$3.26

$0.10

$0.10

$0.05

$0.50

$0.10

$0.10

$0.20

$0.70

$1

$0.20

$0.20

$0.05

$0.20

$0.15

$0.15

$1

$1

$1

Convertible_Promissory_Notes_D

Convertible Promissory Notes (Details) (USD $) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Unpaid Note Principal	$309,428	'
Unpaid Interest & penalty	100,753	'
Notes Payable	410,183	993,554
Note a	'	'
Issue Date	27-Feb-12	'
Unpaid Note Principal	37,500	'
Unpaid Interest & penalty	'	'
Notes Payable	'	40,832
Note b	'	'
Issue Date	3-May-12	'
Unpaid Note Principal	42,500	'
Unpaid Interest & penalty	'	'
Notes Payable	'	67,131
Note c	'	'
Issue Date	18-Sep-12	'
Unpaid Note Principal	13,500	'
Unpaid Interest & penalty	'	'
Notes Payable	'	20,712
Note d	'	'
Issue Date	3-Feb-12	'
Unpaid Note Principal	100,000	'
Unpaid Interest & penalty	'	'
Notes Payable	'	207,500
Note d-2	'	'
Issue Date	8-Jun-12	'
Unpaid Note Principal	50,000	'
Unpaid Interest & penalty	53,997	'
Notes Payable	103,997	100,000
Note e	'	'
Issue Date	17-Dec-12	'
Unpaid Note Principal	80,000	'
Unpaid Interest & penalty	6,645	'
Notes Payable	'	'
Note f	'	'
Issue Date	8-Jan-13	'
Unpaid Note Principal	147,428	'
Unpaid Interest & penalty	6,589	'
Notes Payable	154,017	'
5BARz	'	'
Unpaid Note Principal	277,428	'
Unpaid Interest & penalty	67,231	'
Notes Payable	$344,659	$436,175

Convertible_Promissory_Notes_D1

Convertible Promissory Notes (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Principal Amount	$309,428	'
Note Payable	410,183	993,554
Note a	'	'
Issue Date	27-Feb-12	'
Principal Amount	37,500	'
Date of Maturity	29-Nov-12	'
Interest Rate per annum	8.00%	'
Date	10-Sep-12	'
Note paid off	12,000	'
Common stock issued for debt, shares	401,338	'
Date of arrangement	28-Sep-12	'
Date Due	31-Dec-12	'
Aggregate payments	25,000	'
Price per share	$0.03	'
Note balance payoff	2,771	'
Note Payable	'	40,832
Note b	'	'
Issue Date	3-May-12	'
Principal Amount	42,500	'
Date of Maturity	3-Feb-13	'
Interest Rate per annum	8.00%	'
Note Payable	'	67,131
Note c	'	'
Issue Date	18-Sep-12	'
Principal Amount	13,500	'
Date of Maturity	17-Mar-13	'
Interest Rate per annum	8.00%	'
Accrued interest	16,154	'
Note Payable	'	20,712
Note d	'	'
Issue Date	3-Feb-12	'
Principal Amount	100,000	'
Note Payable	'	207,500
Convertible Debenture Agreement	500,000	'
Convertible Debenture issued to investor	150,000	'
Note Receivable exchange for convertible debenture	400,000	'
Interest Rate	9.00%	'
Alleged damages	2,500,000	'
Note d-2	'	'
Issue Date	8-Jun-12	'
Principal Amount	50,000	'
Note Payable	103,997	100,000
Note e	'	'
Issue Date	17-Dec-12	'
Principal Amount	80,000	'
Interest Rate per annum	8.00%	'
Common stock issued for debt, shares	1,600,000	'
Price per share	$0.05	'
Accrued interest	6,645	'
Note Payable	'	'
Derivative Liability	21,747	'
Note f	'	'
Issue Date	8-Jan-13	'
Principal Amount	147,428	'
Common stock issued for debt, shares	25,000	'
Price per share	$0.05	'
Accrued interest	11,589	'
Note Payable	154,017	'
Convertible Debenture issued to investor	5,000	'
Derivative Liability	$38,271	'

Convertible_Promissory_Notes_D2

Convertible Promissory Notes (Details Narrative) (Parenthetical)	12 Months Ended
	Dec. 31, 2013
Note payments	'
Terms of note	'
	The Company may settle that note within the first 90 days following the issue date by paying to the Lender 140% of the principle amount of the note plus accrued interest. The Company may settle the note during the period which is 91 days from the issue date of the note to 180 days from the issue date of the note by payment of 150% of the principle amount of the note plus accrued interest. In the event that the note is not repaid 180 days from the date of issue, the note is convertible into common stock.
Note d	'
Terms of note	'
	On November 8, 2012, the Company filed an answer, affirmative defenses, and counterclaims, against the plaintiff. On January 3, 2013, the Company entered into a settlement agreement requiring payments in the aggregate amount of $300,000 yielding interest at 9%, and the issuance of 125,000 shares of the common stock of the Company. The Company issued the 125,000 shares on February 12, 2013. On March 13, 2013, an order granting entry of stipulated judgment was granted to La Jolla Cove Investors for payment by the Company of the $300,000 plus interest at 9%. The $300,000 along with 9% interest aggregated $319,307 and has been accrued at September 30, 2013. During the quarter ended September 30, 2013 the Company repaid $70,000, leaving a balance of $249,307 payable at September 30, 2013. Subsequent to September 30, 2013 the Company paid $50,000 on October 23, 2013 and $50,000 on November 12, 2013, leaving a residual balance due of $149,307.

Cellynx_Group_Inc_Convertibles

Cellynx Group, Inc. - Convertibles Promissory Notes (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Unpaid Note Principal	$309,428	'
Unpaid Interest Penalty	100,753	'
Notes Payable	410,183	993,554
Note g	'	'
Issue Date	10-Nov-07	'
Unpaid Note Principal	262,356	'
Notes Payable	'	316,693
Note h	'	'
Issue Date	5-Apr-11	'
Notes Payable	'	98,613
Note i	'	'
Issue Date	5-Jan-12	'
Notes Payable	'	80,438
Note j	'	'
Issue Date	24-May-12	'
Unpaid Note Principal	19,500	'
Unpaid Interest Penalty	18,322	'
Notes Payable	37,822	42,433
Note k	'	'
Issue Date	12-Sep-12	'
Unpaid Note Principal	12,500	'
Unpaid Interest Penalty	15,202	'
Notes Payable	27,702	19,202
CelLnyx	'	'
Unpaid Note Principal	32,000	'
Unpaid Interest Penalty	33,524	'
Notes Payable	$65,524	$557,379

Cellynx_Group_Inc_Convertibles1

Cellynx Group, Inc. - Convertibles Promissory Notes (Details Narrative) (USD $)	12 Months Ended		62 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Face Amount	$309,428	'	$309,428
Settlement of debt	-1,073,009	'	-1,073,009
Common Stock issued for debt, amount	772,441	'	'
Note Payable	410,183	993,554	410,183
Note g	'	'	'
Issue Date	10-Nov-07	'	'
Promissory Note	250,000	'	250,000
Face Amount	262,356	'	262,356
Interest Rate per annum	4.00%	'	4.00%
Settlement of debt	27,500	'	'
Common stock issued for debt, shares	275,000	'	'
Price per share	$0.10	'	$0.10
Note Payable	'	316,693	'
Note h	'	'	'
Issue Date	5-Apr-11	'	'
Promissory Note	50,000	'	50,000
Interest Rate per annum	8.00%	'	8.00%
Common stock issued for debt, shares	603,780	'	'
Price per share	$0.10	'	$0.10
Note Payable	'	98,613	'
Note i	'	'	'
Issue Date	5-Jan-12	'	'
Promissory Note	50,000	'	50,000
Interest Rate per annum	8.00%	'	8.00%
Settlement of debt	170,000	'	'
Common stock issued for debt, shares	440,000	'	'
Price per share	$0.10	'	$0.10
Note Payable	'	80,438	'
Note j	'	'	'
Issue Date	24-May-12	'	'
Promissory Note	37,500	'	37,500
Face Amount	19,500	'	19,500
Interest Rate per annum	8.00%	'	8.00%
Settlement of debt	18,000	'	'
Note Payable	37,822	42,433	37,822
Note k	'	'	'
Issue Date	12-Sep-12	'	'
Face Amount	12,500	'	12,500
Interest Rate per annum	8.00%	'	8.00%
Note Payable	$27,702	$19,202	$27,702

Cellynx_Group_Inc_Convertibles2

Cellynx Group, Inc. - Convertibles Promissory Notes (Details Narrative) (Parenthetical)	12 Months Ended
	Dec. 31, 2013
Note g	'
Terms	'All unpaid principal, together with any then accrued but unpaid interest, shall be due and payable upon the earlier of (i) November 9, 2010 at the written request of the holder to the Company, or (ii) when, upon or after the occurrence of an event of default. The principal amount is convertible into 4.8% of the Company shares outstanding.
Note h	'
Terms	'convert principal and unpaid interest on the note into shares of the Company’s common stock, with the number of shares issuable determined by dividing the amount to be converted by the conversion price which is equal to 63% of the average of the three lowest trading prices of the Company’s common stock over the ten trading days prior to the date of the conversion.
Note i	'
Terms	'Holder may convert principal and unpaid interest on the note into shares of the Company’s common stock, with the number of shares issuable determined to be the amount obtained by dividing the amount to be converted by the conversion price which is the lesser of $0.0013 per share or 63% of the average of the three lowest trading prices of the Company’s common stock over the ten trading days prior to the date of the conversion.

Capital_Lease_Obligation_Detai

Capital Lease Obligation (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Year 2014	$60,000
Year 2015	60,000
Year 2016	50,000
Total Minimum lease payments	170,000
Interest on Lease	9,536
Capitalized valuation of R&D equipment	160,464
Amortization expense of R&D equipment	$7,056

Warrant_Activity_5BARz_Interna

Warrant Activity - 5BARz International Inc. (Details) (USD $) (5BARz, USD $)	12 Months Ended
	Dec. 31, 2013
5BARz	'
Warrant Activity	'
Outstanding Warrants, beginning	2,140,000
Granted, Number of shares	47,040,103
Cancelled, Number of shares	1,600,000
Outstanding and exercisable, Number of Warrants	47,580,103
Weighted Average Exericse Price	'
Outstanding at December 31, 2012	$0.20
Granted, Weighted average exercise price	$0.26
Cancelled, Weighted average exercise price	$0.20
Outstanding and exercisable, Weighted average exercise price	$0.26
Outstanding, Average Remaining Contractual Life	'1 year 6 months 4 days

Options_Exercisable_5BARz_Deta

Options Exercisable 5BARz (Details) (USD $) (5BARz, USD $)	12 Months Ended
	Dec. 31, 2013
5BARz	'
Options exercisable [Abstract]	'
Beginning, Number of Options	0
Options, Granted	4,000,000
Options, Exercised	'
Options, Cancelled	'
Ending, Number of Options	4,000,000
Ending,Number of Options, outstanding and exercisable	1,079,452
Weighted Average Exercise Price	'
Weighted Average Exercise Price	$0
Weighted Average Exercise Price, Granted	$0.10
Weighted Average Exercise Price, Exercised	'
Weighted Average Exercise Price, Cancelled	$0
Weighted Average Exercise Price	$0.10
Weighted Average Remaining Contractual Life	'2 years 5 months 0 days

Options_and_Warrants_5BARz_Det

Options and Warrants 5BARz (Details) (USD $)	12 Months Ended		62 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Stock options commitment expense	$601,113	'	$601,113

Options_Exercisable_CelLynx_De

Options Exercisable CelLynx (Details) (CelLynx, USD $)	12 Months Ended
	Dec. 31, 2013
CelLynx	'
Options exercisable [Abstract]	'
Beginning, Number of Options	6,400,000
Options, Granted	65,000,000
Options, Cancelled	6,400,000
Ending,Number of Options, outstanding and exercisable	65,000,000
Weighted Average Exercise Price	'
Weighted Average Exercise Price	$0.00
Weighted Average Exercise Price, Granted	$0.00
Weighted Average Exercise Price, Cancelled	$0.00
Weighted Average Exercise Price	$0.00
Weighted Average Remaining Contractual Term, beginning	'2 years 5 months 0 days
Weighted Average Remaining Contractual Life	'4 years 6 months 0 days

Options_Assumptions_CelLynx_De

Options Assumptions CelLynx (Details) (CelLynx, USD $) (USD $)	12 Months Ended		62 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Stock options commitment expense	$601,113	'	$601,113

Warrant_Activity_CelLynx_Group

Warrant Activity - CelLynx Group, Inc. (Details) (USD $) (CelLynx Group, Inc., USD $)	12 Months Ended
	Dec. 31, 2013
CelLynx Group, Inc.	'
Warrant Activity	'
Outstanding Warrants, beginning	5,930,000
Granted, Number of shares	'
Exercised, Number of shares	'
Expired, Number of shares	1,430,000
Outstanding and exercisable, Number of Warrants	4,500,000
Weighted Average Exericse Price	'
Outstanding at December 31, 2012	$0.12
Granted, Weighted average exercise price	'
Exercised, Weighted average exercise price	'
Expired, Weighted average exercise price	$0.12
Outstanding and exercisable, Weighted average exercise price	$0.96
Outstanding, Average Remaining Contractual Life	'1 year 1 month 5 days

Related_Party_transactions_Det

Related Party transactions (Details) (USD $)	12 Months Ended		62 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Nov. 07, 2013	Sep. 18, 2013
Related Party Transactions [Abstract]	'	'	'	'	'
Date of Agreement	30-Dec-10	'	'	'	'
Proceeds from Note Payable	$370,000	'	'	'	'
Issuance of Common Stock	15,600,000	'	'	'	'
Payment on Note	19,850	100,587	464,172	'	'
Payment due to Related Party	'	19,850	'	50,000	15,000
Consulting Fees	$71,000	'	'	'	'

Investment_in_5BARz_AG_Details

Investment in 5BARz AG (Details Narrative) (5BARz AG, USD $)	0 Months Ended	12 Months Ended
	Oct. 06, 2011	Dec. 31, 2013
5BARz AG	'	'
Subsidiary or Equity Method Investee [Line Items]	'	'
5BARz AG Common stock issued, shares	10,000,000	'
5BARz AG Common stock issued held by company, shares	5,100,000	9,428,000
5BARz AG Common stock issued held by officers and a consultant, shares	450,000	'
5BARz AG Common stock in escrow, shares	4,450,000	'
5BARz AG Common stock, Par Value	'0.01 CHF	'0.01 CHF
Common Stock Sold, in shares	'	30,000
Proceeds of Common Stock	$108,752	$100,710
Acquired interest	'	94.30%

Acquisition_of_CelLynx_Group_I

Acquisition of CelLynx Group, Inc.Description (Details Narrative) (USD $)	1 Months Ended	12 Months Ended	0 Months Ended	3 Months Ended
	Mar. 29, 2012	Dec. 31, 2012	Jan. 07, 2011	Mar. 29, 2012
			CelLynx Group, Inc.	CelLynx Group, Inc.
Common Stock recieved from CelLynx Group, Inc.	'	'	63,412,638	'
Purchase Price for common stok of CelLynx Group, Inc.	'	$250,000	$634,126	'
Cash consideration paid	170,000	'	170,000	'
Common Share of the registrant issued	'	'	1,250,000	'
Amount of credit facility converted to capital stock of CelLynx Group, Inc.	'	'	'	73,500
Amount of Shares of CelLynx Group, Inc. resulting from conversion of credit facility	'	'	'	350,000,000
Intrinsic value of embedded conversion feature	'	'	'	$381,500

Investment_in_CelLynx_Group_In2

Investment in CelLynx Group, Inc. (Details) (USD $)	1 Months Ended
	Mar. 29, 2012
Business Combinations [Abstract]	'
Cash consideration paid	$170,000
1,250,000 common shares of the registrant issued at a market price of $0.20 per share	250,000
Redemption of convertible debt for 350 million shares of Cellynx Group Inc. common stock	455,000
Fair market value of consideration paid	$875,000

Investment_in_CelLynx_Group_In3

Investment in CelLynx Group, Inc. (Details) (Parenthetical) (USD $)	1 Months Ended
	Mar. 29, 2012
Common Stock For Cellynx	'
Common Share of the registrant issued	1,250,000
Common Stock recieved from Cellynx Group, Inc.	63,412,638
Common Stock	'
Price Per Unit	0.2

Investment_in_CelLynx_Group_In4

Investment in CelLynx Group, Inc. - Assets and Liabilites recognized (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Mar. 29, 2012	Mar. 29, 2012	Mar. 29, 2012
			Net book Value of Cellynx	Adjustments	Valuation attributed to assets acquired
Current assets	'	'	$3,260	'	$3,260
Patents, trademarks, and license	'	'	44,718	1,155,282	1,200,000
Investment in 5BARz	'	'	1,800,000	'	1,800,000
Furniture and equipment	'	'	2,113	'	2,113
Accounts payable and accruals	'	'	-1,756,628	'	-1,756,628
Notes payable (net of discount)	'	'	-403,076	'	-403,076
Accrued Interest	'	'	-62,250	'	-62,250
Derivative liability	'	'	-5,495,425	-5,026,093	-469,332
LOC payable-5BARz (net)	'	'	-586,525	-586,525	0
Fair value non-controlling interest	'	'	'	-583,333	-583,333
Totals	'	'	-6,449,813	6,184,567	-265,246
Goodwill	1,140,246	1,140,246	'	'	1,140,246
Purchase price	'	'	'	'	$875,000

Acquisition_of_CelLynx_Group_I1

Acquisition of CelLynx Group, Inc. (Details Narrative) (CelLynx Group, Inc., USD $)	0 Months Ended
	21-May-13	15-May-12	Apr. 13, 2012
CelLynx Group, Inc.	'	'	'
Conversion of debt	$9,375	$58,500	$7,700
Common Stock Recieved, share	375,000,000	390,000,000	51,333,333

Acquisition_of_CelLynx_Group_I2

Acquisition of CelLynx Group, Inc. - Proforma Financial Statements(Details Narrative) (CelLynx Group, Inc., USD $) (USD $)	12 Months Ended
	Dec. 31, 2012
Acquisition Of Cellynx Group Inc. - Proforma Financial Statementsdetails Narrative Cellynx Group Inc. Usd	'
Revenues	$0
Net loss	($1,070,117)
Pro forma basic and diluted net loss per common share	($0.01)
Pro forma weighted average common shares outstanding-basic and diluted	97,833,528

Litigation_Details_Narrative

Litigation (Details Narrative) (USD $)	12 Months Ended
	Dec. 31, 2013
Stock Issued During Period	$772,441
Note payable	103,997
Labor Commission	'
Date	'7/19/2010
Allegations	'Unpaid Wages
Alleged Damages	263,003
LaJolla Cove Investors Inc.	'
Date	'10/16/2012
Allegations	'Breach of contract
Alleged Damages	2,500,000
Legal Fees	300,000
La Jolla Cove Dimissal	'
Date	'1/13/2013
Allegations	'Dimssing Action
Alleged Damages	300,000
Interest Rate per annum	9.00%
Common stock issued for debt, shares	125,000
Stock Issued During Period	220,000
Asher Enterprises, Inc.	'
Date	'3/22/2013
Allegations	'Repayment of notes
Alleged Damages	81,000
Payment on Loan	$70,805

Litigation_Details_Narrative_P

Litigation (Details Narrative) (Parenthetical)	12 Months Ended
	Dec. 31, 2013
LaJolla Cove Investors Inc.	'
Damages Sought	'On January 3, 2013, the Company and La Jolla Cove Investors, Inc. entered into an agreement for the settlement of the lawsuit for proceeds of $300,000 plus accrued interest from the date of the settlement agreement at a rate of 9%, plus the delivery of 125,000 shares of the common stock of the Company. On January 13, 2013 a stipulation dismissing action without prejudice and without award of attorney’s fees or costs was entered. On March 8, 2013 as a result not meeting the stipulated payment schedule, La Jolla Cove was awarded a judgment in the amount of $300,000 plus accrued interest at a rate of 9% from the date of the settlement agreement. During the year ended December 31, 2013, the Company issued the 125,000 shares and made payments aggregating $220,000 in settlement of the amounts due. Notes payable reflected in the consolidated financial statements at December 31, 2013 include $103,997 of unpaid principle and interest remaining outstanding on this claim.
Asher Enterprises, Inc.	'
Damages Sought	'The claims allege that damages in the amount of the greater of; (i) 200% x $81,000, the remaining outstanding principle amount of the Note, together with accrued and unpaid interest in the unpaid principle amount of the Notes, plus default interest; or (ii) the “parity value” of the “default amount” paid in shares as defined in the terms of the agreements. The Company intends to file an appearance and defend against the law suit.

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	12 Months Ended			62 Months Ended	0 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2013	Mar. 06, 2014		Mar. 14, 2014	Feb. 10, 2014	Jan. 15, 2014	Feb. 10, 2014
					Subsequent Event		Subsequent Event	Subsequent Event	Subsequent Event	Additional Subsequent Event
Units Issued	'	'	'	'	6,375,000		3,733,333	'	'	'
Proceeds from Sale of Warrants	'	'	'	'	$637,500		$560,000	'	'	'
Aggregate Proceeds	228,740	798,463	7,500	'	'		'	'	'	'
Shares issued for Services, shares	'	'	'	'	'		'	405,581	'	1,250,000
Shares issued for Services, amount	601,113	'	'	601,113	'		'	100,000	'	287,500
Common stock issued for debt, shares	'	'	'	'	'		'	'	100,000	'
Price of Stock	'	'	'	'	$0.30		$0.30	$0.25	$0.17	$0.23
Price per share	'	'	'	'	$0.10	[1]	$0.15	'	$0.17	'
Stock Issued During Period	772,441	'	'	'	'		'	'	'	'
Settlement of debt for common stock	'	'	'	'	'		'	'	$16,700	'
Strock option, shares	'	'	'	'	'		'	'	8,150,000	'
[1]	Each unit is comprised of one share and one warrant to acquire a second share, with a two year warrant term.